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ABSTRACT 
Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4) that belongs to a new class of immunotherapeutic drugs called immune 
checkpoint inhibitors (ICI) which prevent the feedback inhibition of activated T cells and 
hold great promise to treat cancer. Indeed, it has been demonstrated that ipilimumab 
increases overall survival (OS) of metastatic melanoma patients, but a durable 5-year 
survival benefit is observed in a proportion of patients ranging from 12% to 49% and, the 
treatment has mild to severe immune-related adverse events (irADR). In this context, the 
development of reliable biomarkers is of great importance to select patients with higher 
possibility to benefit from this treatment. In this respect, immune profiling could play a 
significant role, and, in particular, the monitoring of myeloid-derived suppressor cells 
(MDSC), which are predictive of OS and response to chemotherapy in many types of 
cancer, and thus represent a promising biomarker also for response to ICI. However, the 
validation of the predictive significance of MDSCs is challenged by the phenotypic 
complexity of these cells, that lacks an international consensus on the minimal 
requirements for MDSC monitoring.  
To meet this request, we organised the first proficiency panel to harmonize human MDSC 
phenotyping in collaboration with the Cancer Immunoguiding Program. Hence, we 
proceeded to the first phase, that consisted in phenotyping three batches of PBMC 
distributed to the 23 participating laboratories. We also analysed data from the 23 
laboratories and observed that the quantification of MDSCs across different laboratories 
was affected by high variance, and we identified some parameters responsible for the 
high heterogeneity of results. Results of this first step will set the basis for the second step 
which is expected to reduce inter-laboratory variance.  
From this experience, we developed a standardized approach to monitor the circulating 
levels of four MDSC subsets in melanoma patients undergoing ipilimumab treatment. 
These results were included in a wide dataset together with other tumor-associated and 
immunological parameters (TIPs) and used to identify early predictors of OS and toxicity 
through a multivariate non-parametric statistical approach.   
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We followed the variations of TIPs during ipilimumab treatment and identified two 
immune profiles predictive of OS. The immune profile of patients with better prognosis 
included: lower baseline levels of IL-6, CRP and VEGF and higher post-treatment 
frequencies of CD3+ T cells and CD4+/CD279+ T cells. On the other hand, patients with 
worse prognosis presented higher post-treatment levels of MDSC1 and 2 and of CD8+/PD-
1+ T cells. In addition, the development of grade 3 irADR was negatively associated to the 
levels of CD3+ and CD4+/PD-1+ T cells and of eosinophils, while positively associated to an 
increased variance of MDSC4. In conclusion, we demonstrated that the monitoring of the 
immunological correlates has the potential to identify patients with better prognosis 
following ipilimumab treatment, thus guiding a more rational use of this therapy.  
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RIASSUNTO 
Ipilimumab è un anticorpo monoclonale diretto contro cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) e appartiene a una nuova classe di farmaci immunoterapeutici chiamati 
immune checkpoint inhibitors (ICI). Questi farmaci prevengono la fisiologica inibizione 
dell’attivazione dei linfociti T e costituiscono una promettente terapia per la cura del 
cancro. Infatti è stato dimostrato che ipilimumab è in grado di aumentare la sopravvivenza 
dei pazienti affetti da melanoma metastatico. Tuttavia il farmaco produce una 
sopravvivenza stabile a 5 anni in una parte variabile dei pazienti trattati (12-49%) e inoltre 
può comportare effetti collaterali con eziologia di tipo immunologico (irADR) di grado 
medio o alto. Risulta quindi importante identificare biomarcatori che siano in grado di 
discriminare i pazienti con più alta probabilità di trarre beneficio da questo tipo di 
trattamento. A tal fine può essere importante tracciare un profilo immunologico del 
paziente, e in particolare monitorare i livelli circolanti di cellule soppressorie di 
derivazione mieloide (MDSC). Infatti i livelli circolanti di queste cellule sono stati associati 
a una minor sopravvivenza e risposta a trattamenti chemioterapici in diversi tipi di cancro, 
e quindi possono avere un ruolo potenzialmente predittivo anche nei confronti della 
risposta agli ICI. Tuttavia la validazione del potere predittivo delle MDSC si deve scontrare 
con la complessità fenotipica di queste cellule e con la mancanza di un consenso 
internazionale circa la definizione da applicare per il loro monitoraggio.  
Per cercare di dare una risposta a questi problemi, abbiamo organizzato in collaborazione 
con il Cancer Immunoguiding Program, un pannello internazionale di armonizzazione del 
fenotipo delle MDSC. Attualmente è stata completata la prima fase che consisteva nel 
fenotipizzare tre campioni di cellule mononucleate da sangue periferico da parte dei 23 
laboratori partecipanti. Analizzando i dati provenienti da questi 23 laboratori abbiamo 
osservato che la quantificazione delle MDSC presentava un’alta varianza e abbiamo 
identificato alcuni dei parametri responsabili di tale eterogeneità. I risultati di questa 
prima fase sono le fondamenta per la progettazione della seconda fase da cui ci 
aspettiamo una riduzione della varianza tra i diversi laboratori.  
L’esperienza maturata con il pannello di armonizzazione ci è servita per sviluppare un 
metodo standardizzato per il monitoraggio di quattro sottopopolazioni di MDSC circolanti 
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in pazienti affetti da melanoma e in trattamento con ipilimumab. Questi risultati assieme 
ai valori di altri parametri, associati al tumore o al profilo immunologico del paziente 
(TIPs), sono stati elaborati con metodi statistici multivariati e non-parametrici atti ad 
individuare dei marcatori precoci di sopravvivenza e tossicità in risposta al trattamento 
con ipilimumab.  
Grazie al monitoraggio dei livelli di questi parametri durante la terapia con ipilimumab, è 
stato possibile individuare due profili predittivi di sopravvivenza. I pazienti con migliore 
prognosi hanno minori livelli basali di IL-6, CRP e VEGF e maggiori livelli di linfociti T, in 
particolare della sottopopolazione CD4+/CD279+ al termine della terapia. Al contrario, una 
ridotta sopravvivenza si accompagna a maggiori livelli di MDSC1-2 e di linfociti T CD8+/PD-
1+ post-trattamento. Inoltre lo sviluppo di irADR di grado 3 è inversamente correlato con 
i livelli di linfociti T (CD3+ e CD4+/PD-1+) e di eosinofili, mentre è direttamente correlato 
con un aumento nella varianza dei valori di MDSC4. In conclusione questo studio ha 
dimostrato che le modificazioni del profilo immunologico associate al trattamento con 
ipilimumab possono dare informazioni sulla prognosi del paziente e quindi indirizzare le 
scelte cliniche verso un uso più razionale di questo tipo di terapia.  
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INTRODUCTION 
A historical overview of the tumor immunology: from the concept of 
immunosurveillance to the cancer immunoediting theory  
The idea that the immune system can control growing tumors was formally enunciated by Burnet 
and Thomas in the hypothesis of cancer immunosurveillance1. According to this theory, malignant 
transformation naturally occurs in the body as a result of genetic changes, but tumors do not 
become clinically detectable because they are eliminated by the immune system which recognises 
the new antigenic determinants expressed on their surface. The higher incidence of cancer in 
immunodeficient or transplanted patients constituted an early evidence supporting the 
immunosurveillance theory2,3. However, the long-term follow up of these patients revealed that 
this high risk was partially explained by an impaired natural protection against oncogenic virus4, 
and similar findings were observed also in mice with induced immunodeficiency5. In the same 
years, the hypothesis of immunosurveillance was further challenged by the work of Stuntman and 
colleagues demonstrating that athymic nude mice did not developed spontaneous or chemical-
induced tumors with a higher rate than immunocompetent controls6. At that time, these results 
constitutes an important proof against the hypothesis of cancer immunosurveillance, but it is now 
clear that those results were affected by a major pitfall. Indeed, nude mice are not completely 
immunodeficient, as they were considered at that time, but, on the contrary, they still possess 
myeloid cells, natural killer cells (NK) and B lymphocytes, which can thus provide a reduced, but 
sufficient, anti-tumor immunity. Some decades afterwards, the improved knowledge in the field 
of tumor immunology and important technological discoveries brought about a renewed interest 
in the theory of cancer immunosurveillance. In particular, the development of transgenic and 
knoc-out mice lacking NK, T and B lymphocytes finally provided strong and convincing data in 
favour of cancer immunosurveillance7-9. Indeed, RAG1-2-/- mice failed to control both chemical-
induced and natural occurring carcinogenesis10 and, since the impairment of their immune system 
is confined only to lymphocytes, these results constitutes an important evidence that these cells 
play a major role in the surveillance of nascent tumors. In fact, previous studies have already 
demonstrated that IFN-, a cytokine produced by T cells, block the growth of transplanted 
tumors11 but Shankaran et al., definitively proved that lymphocytes and IFN- block the formation 
of chemical-induced tumors in a synergic fashion10 . The clinical relevance of tumor-infiltrating T 
lymphocytes (TIL) was recently investigated by Galon and colleagues in the context of human 
colorectal carcinoma in which they demonstrated that a massive infiltration of T cells is associated 
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with better prognosis of patients and it constitutes a discriminating parameter for the choice of 
the therapeutic approach applied after the resection of primary colorectal cancer12. 
Albeit from the late 1990s the hypothesis of immunosurveillance lived a period of renaissance, 
this concept finds its intrinsic caveat in the fact that microscopic neoplasia can often overwhelm 
the immune control and thus become clinically detectable. In fact, a number of experiments 
revealed that the immune system exerts both a host-protective and tumor-sculpting effect on 
developing malignancies (reviewed in Dunn7). A striking evidence of this phenomenon is that 
tumors formed in immune-competent mice fails to be immunogenic when transplanted into a 
second immune-competent host, while tumors developed in an immunodeficient animal are then 
effectively rejected upon transfer in an immune-competent recipient10. As a consequence, Robert 
Schreiber and colleagues believed that the original immunosurveillance theory was no longer 
appropriate to fully describe the interaction between immunity and tumors, and they proposed 
to use the broader term “cancer immunoediting” to explain the ambivalent behaviour of the 
immune system towards cancer7.  
 
Figure 1: The three Es of cancer immunoediting 
The three Es of cancer immunoediting refers to ‘Elimination’, ‘Equilibrium’, and ‘Escape’. Elimination: 
the development of tumor is kept in check by the immunosurveillance. Equilibrium: tumor cells that 
have survived the immune surveillance are in balance with immunity of the host. Escape: tumor  cells 
grow and overwhelm the control of the host immune system. (Dunn et al. Immunity, 2004) 
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According to the “cancer immunoediting” theory, the crosstalk between cancer and immune 
system results from three processes: Elimination, Equilibrium and Escape (Figure 1). The original 
idea of immunosurveillance is included in the elimination phase in which the growth of a growing 
tumor is controlled by the immune system. This phase corresponds to the theory of 
immunosurveillance, if the tumor is completely eliminated by the immune system. However, if 
the elimination of the tumor is incomplete, then a second phase takes place, called the equilibrium 
phase, in which the genetic instability of malignant cells gives rise to low-immunogenic clones that 
have a higher probability to survive in an immune-competent host and are therefore favoured in 
the Darwinian selection of tumor variants. In the equilibrium phase, the tumor is not yet clinically 
apparent because the immune system is still able to control the growth of the majority of 
malignant cells. If this equilibrium phase breaks, the third phase of cancer immunoediting, called 
escape phase, takes place. This phase can be achieved only if cancer cells become able to suppress 
the immune system and can therefore expand in uncontrolled manner becoming clinically 
detectable (reviewed in7). The concept of cancer immunoediting is now considered a pillar of 
tumor immunology and, indeed, in 2011 Hanahan and Weiberg acknowledged immune escape as 
an important hallmark of cancer13.  
The concept of tumor microenvironment 
Different types of leukocytes infiltrate the tumors having a beneficial as well as a deleterious 
action on disease progression, but the tumor microenviroment is far from being composed only 
of immune cells14. Indeed, stromal cells, like fibroblasts, shape and sustain the complex 
architecture of cancer, and vascular endothelial cells formed blood vessels supporting the 
nutritional requirements of the growing mass.  Even if these ancillary cells do not belong to the 
hematopoietic lineage, they are included in the definition of immune contexture because they can 
take part in the modulation of immunity within the tumor mass15. The purpose of this section is 
to give a brief overview of the nature and the function of the players composing the tumor 
microenvironment with a special focus on their ability to modulate immunity in favour of 
malignant cells.  
Most of the immunological contexture is composed of infiltrating leukocytes belonging both to 
innate and acquired immunity (reviewed in 14). The leukocytes mainly involved in tumor 
eradication are T lymphocytes and they are characterized by high specificity of action due to their 
antigen specificity. T cells can be classified in two main subsets according to expression of the two 
co-receptors CD4 and CD8: CD4 is expressed both by T helper (Th) and regulatory T cells (Treg), 
while CD8 is a marker of cytotoxic T lymphocytes (CTL)16. CTL are able to destroy malignant cells 
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upon recognition of antigens presented on MHC I molecules by the cancer cells16. However, as 
antigen presentation by tumor cells is often inefficient17, the effective recognition of antigens by 
CD8+ cells could occur also via cross-presentation on MHC I molecules by antigen presenting cells 
18. On the other hand, tumor antigens could be presented to T lymphocytes also by MHC II 
molecules, recognized by CD4+ Th cells which activate a variety of immune cells through ligand-
dependent interactions and secretion of cytokines16. Immune infiltrates characterized by high 
CD8+ cells and memory T cells are prognostic of better diseases control while association between 
CD4+ cells and clinical outcome is more controversial (reviewed in 15). Albeit a T cell infiltrate is 
generally associated with better prognosis, studies on melanoma revealed that TIL have blunted 
functions that can be rescued after a period of in-vitro culture19. Indeed, several mechanisms are 
known to limit T cell functions in the tumor milieu. The main mechanism of negative regulation of 
T cells is the induction of exhaustion20, a process characterized by expression of multiple inhibitory 
receptors on T cells which impair their activation and effector functions21, and generation of 
regulatory T cells capable of directly suppressing the T cell response22.  
The innate immunity could contribute to tumor elimination through short-lived responses 
mediated mainly by NK and natural killer T cells (NKT) (reviewed in 23). However, tumors are able 
to impair also the action of innate cytotoxicity and indeed intra-tumoral NK cells are often 
anergic24.  
Myeloid cells are the leukocytes characterized by the strongest ambivalence. In fact, on one side 
myeloid dendritic cells and M1 macrophages are responsible of efficient antigen presentation and 
contribute to the immune attack towards malignant cells, but on the other side several myeloid 
cells can prevent or suppress anti-tumor immunity (reviewed in 25). M2 macrophages, 
plasmacitoid dendritic cells and myeloid-derived suppressor cells (MDSC) are key suppressive 
players and, albeit each subset is provided with specific suppressive machinery, they share some 
characteristics like the expression of ligands for immune checkpoint molecules (i.e PDL-1), the 
production of suppressive cytokines (i.e. IL-10) and the activation of indoleamine-2,3-dioxygenase 
(IDO) (reviewed in 14).  
An important contribution to the immunological contexture is given by stromal cells like fibroblast, 
vascular endothelial cells and extracellular matrix. These components shape the architecture of 
cancer and can impede immune infiltration through a direct physical barrier26 or can contribute 
to immune evasion actively participating to immune suppression27. For example, a recent study 
by Zhang et al. demonstrated that fibrocytes represents a novel subsets of MDSCs present in the 
blood of cancer patients28.  
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The coordination of this dynamic interplay between immune players, stromal cells and cancer is 
orchestrated by a variety of cytokines and chemokines. High expression of CX3CL1, CXCL9 and 
CXCL10 is associated with infiltration of effector and memory T cells29 while the CCR4 - CCL22 axis 
drives the trafficking of suppressor cells30. Moreover, a recent study indicates that production of 
reactive nitrogen species within the tumor microenvironment results in nitration of CCL2 which 
results in a hindered T cell infiltration31. On the other hand, cytokines are more involved in shaping 
the functional properties of the immune contexture. There are cytokines with direct suppressive 
function like IL-10 and TGF-, while cytokines classically involved in inflammation, like GM-CSF or 
IL-6, could mediate immune suppression through induction of MDSCs25,32. 
Immunotherapy of cancer 
The increasing comprehension of the mechanisms involved in the relationship between cancer 
and the immune system shed light on the possibility to manipulate these interactions in favour of 
cancer therapy. The early attempts to exploit an immune reaction to cure cancer came from the 
studies using Coley’s toxin or Bacillus Calmette-Guerin33,34 while the first immunotherapy 
approach consisted in the administration of cytokines like IL-2 or IFN- which either sustain T cells 
proliferation35 or have a broader anti-proliferative effect on malignant cells36. A rush in the 
development of immunotherapy began in 1970s thanks to the improved knowledge of tumor 
immunology and important technological discoveries which guided the development of modern 
immunotherapeutics consisting in antibodies, cytokines, vaccines and cellular therapy (reviewed 
in 37). 
The revolution started with the discovery of the hybridoma technology in the 1970s38. This 
technique permits a large scale production of epitope-specific murine antibodies (monoclonal 
antibodies – mAb) that could be used either for cancer treatment or to implement diagnostics. 
The first therapeutic mAbs were targeted to tumor antigens and induced effective complement- 
and cell-dependent lysis of the tumors but the results were characterized also by unexpected 
toxicity (reviewed in 37) due to inter-species cross-reaction. The production of fully human mAbs 
solved this problem and nowadays many antibodies of this kind are commonly used as drugs39. 
The distribution of mAbs depend on the degree of vascularisation of the tumor but, when this 
requirement is fulfilled, they can function also as carriers for radioisotopes, toxins or 
chemotherapy. Recently, research went beyond tumor-specific mAbs and developed a new class 
of mAbs targeted to regulators of immune response called immune checkpoints40. These 
molecules are exposed on T cells and can act either as negative or positive regulators of T cell 
response. Ipilimumab and pembrolizumab, two mAbs blocking negative regulators of T cells are 
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the first immune checkpoint inhibitors approved by the Food and Drug Administration (FDA)41,42, 
while other mAbs with immune-stimulatory functions are under development (reviewed in 43). 
The discovery of tumor-associated antigens resulted in different strategies of therapeutic 
vaccination for cancer (reviewed in 44). The road toward an efficient vaccination protocols is an 
example of how advancements in tumor immunology are translated to clinical protocols in order 
to implement cancer immunotherapy. Indeed, the first vaccines were based on administration of 
whole tumor cells derived either from autologous or allogeneic tumors. These cells were 
inactivated by radiation and their immunogenic potential was enhanced by chemical treatment or 
genetic manipulation in order to secrete immune activating cytokines like GM-CSF and IL-244. 
However, the efficacy of these treatments was not confirmed by phase III clinical studies, and 
therefore subsequent efforts have been invested to enhance the immunogenic potential of 
vaccines. In particular, many studies focused on boosting antigen presentation of tumor antigens, 
through the use of activated and polarised dendritic cells pulsed with autologous tumor lysate in 
order to convey an efficient and specific response against the tumors45,46. Sipuleucel T is a vaccine 
composed of autologous dendritic cells pulsed with prostatic acid phosphatase antigen and 
activated with GM-CSF is the only vaccination protocol approved by FDA for cancer treatment47. 
The experience reached in the field of cancer vaccines offered a paradigm that could be applied 
to the other immunotherapeutic approaches: an effective immune rejection of cancer can be 
obtained only by properly stimulating and activating the immune effector cells, and the general 
level of immune suppression must be taken into account, and eventually ablated, to reach the 
proposed therapeutic effects.  
Following this rationale, cancer vaccination can be effective when the immunity of the patient is 
functional, but if a deeper impairment is present, adoptive cell transfer (ACT) should be preferred 
in order to supply the suppressed natural immunity with new functional effector cells48. The first 
attempts to generate a de-novo immune response against cancer were pioneered by S. Rosenberg 
and collaborators who isolated TIL from melanoma biopsies and re-infused these cells into 
patients after a period of in-vitro activation, thus obtaining a complete and durable eradication of 
the tumor in some patients49. Following this experience, over the years many other groups 
contributed to implement ACT with natural occurring TILs or with autologous lymphocytes bearing 
an engineered T cell receptor with higher affinity for cancer cells50. The same procedures have 
been applied also to NK and NKT cells which can be activated in-vitro with specific cocktails of 
cytokines and re-injected as lymphokine-activated killer (LAK) or cytokine-induced killer (CIK), 
respectively51,52. The major obstacle of these approaches is that patients must undergo a 
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preparative lymphodepletion and must be infused with high doses of IL-2, to sustain the efficacy 
of ACT, and this treatment has a high toxicity and must be managed only by highly specialized 
centres48.  
A novel strategy to implement ACT is to eradicate the suppressive network present in the tumor 
by combinatorial approaches like adding a cycle of chemotherapy, radiation or targeted therapy 
to deplete suppressive leukocytes prior to ACT (reviewed in 53,54). Another strategy to boost the 
activation of transferred T cells is to combine ACT with immune checkpoint blockade, and the 
efficacy of this approach is currently under clinical investigation54. 
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Myeloid-derived suppressor cells as key players in the immune suppression of 
tumors 
The first studies describing myeloid cells endowed with suppressive capability dated back to the 
late 1990s55,56, and they were followed by a number of studies further describing the suppressive 
potential of myeloid cells characterised by different stages of maturation and distinct phenotypes 
(reviewed in 57). These cells were often addressed as “immature myeloid cells” or “suppressive 
myeloid cells” but neither of these names seemed accurate. In 2008 a group of leading scientists 
in the field proposed to find a new acronym to unequivocally identify cells of myeloid origin, 
displaying an impaired differentiation and endowed with immune-suppressive functions which 
were often induced under pathological conditions, especially in cancer58. As a result, the acronym 
myeloid-derived suppressor cells (MDSC) which is now in use. 
It has been demonstrated that MDSCs can be induced by some pathological conditions, from 
infection to autoimmune diseases and their level seems to increase also with age59, but MDSCs 
were originally identified in cancer25. Indeed, our group has demonstrated that MDSCs can be 
induced in-vitro from bone marrow progenitors by adding a cocktail of cytokines, commonly 
secreted by the tumors32. Nevertheless, there are some factors that seem to be more involved in 
the development of MDSCs and they comprehend a number of pro-inflammatory cytokines (GM-
CSF, IL-6, S100A8, S100A9, prostaglandins) but also angiogenic factors like vascular endothelial 
growth factor (VEGF). Several groups demonstrated the link between tumor-derived factors and 
MDSC expansion60-62, and several associations between the levels of pro-inflammatory factors and 
the circulating levels of MDSCs have been reported also in patients with cancer (reviewed in 63).  
Phenotype of mouse MDSCs 
MDSCs were originally identified in mice by using the combination of the myeloid markers CD11b 
and Gr-164. Further studies elucidated that CD11b+/Gr-1+ cells are not a homogeneous cell 
population, but rather a heterogeneous collection of myeloid cells, endowed with different 
suppressive ability. At present, it is well known that there are at least two main subsets of MDSCs 
present in tumor-bearing mice, one monocytic and one granulocytic, and these populations can 
be properly identified by using a set of accessory markers. In particular the differential expression 
of Ly6C and Ly6G, the two isoforms of Gr-1, allow the identification of granulocyic MDSC (G-MDSC) 
as CD11b+/Gr-1high/Ly6C-/Ly6Ghigh and monocytic MDSCs (M-MDSC) as CD11b+/Gr-
1int/Ly6Chigh/Ly6G- 57. The appropriate definition of these subsets is important in view of their 
differential localization and suppressive power. Indeed, several studies demonstrated that G-
MDSC are mostly located in the secondary lymphoid organs while M-MDSC constitutes the 
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majority of immune suppressive cells at the tumor site. This is intriguing considering that M-MDSC 
are endowed with a higher suppressive capability than G-MDSCs, on a per cell basis65-67. Other 
potential markers have been proposed to identify the two main subsets, like CD124, CD115, CD40, 
CD49d, CD244, but as these markers are shared also by inflammatory monocytes and neutrophils, 
a suppressive assay is always required for a complete definition of MDSCs57. A good surrogate for 
phenotypic definition of MDSCs is the expression of the  chain of interleukin-4 receptor (IL4R 
or CD124) which has been implicated also in MDSC function and survival68,69 and it is express also 
by human MDSCs70,71.  
Phenotype of human MDSCs 
The phenotypic characterization of human MDSCs is hampered by the lack of a specific marker, 
and by the absence of a homologue of the murine Gr-1; therefore, pan-myeloid markers like 
CD11b or CD33, are used to define MDSCs in humans, together with lineage-specific markers. 
Indeed, three main classes of MDSCs with distinct lineage-commitments have been identified in 
the blood of cancer patients: monocytic, granulocytic and immature MDSCs. M-MDSCs are 
characterized by the expression of CD14 and frequently presented a downregulation of HLA-DR 
and enhanced IL4R expression70,72. G-MDSCs are characterised by the expression of markers 
specific of the polymorphonuclear lineage like CD15 and CD66b and could be detected both in 
low- and high-density polymorphonuclear cells (LD-PMN, HD-PMN)73,74. This definition is based on 
the behaviour of PMN during density gradient separation: LD-PMN co-stratify with peripheral 
blood mononuclear cells (PBMC) while HD-PMN have a higher density and therefore lay below the 
PBMC layer, on the top of erythrocytes. G-MDSC belonging to LD-PMN are generally defined as 
CD14-/CD15+/CD66b+/CD11b+/SSCint 75 while those included in HD-PMN are characterized by 
expression of IL4R and high side scatter (SSC)70. Immature MDSCs (I-MDSCs) are a cell subset 
that do not express the markers of mature immune cells like lymphocytes, monocytes and 
granulocytes76,77. As a consequence, they stain negative for an antibody cocktail containing 
markers of mature leukocytes (Lineage cocktail) and they also show a low expression of HLA class 
II, which is peculiar of immature cells. I-MDSCs (Lineage-/HLA-DR-/CD33+/CD11b+) circulating in 
the peripheral blood of patients with solid tumors have a phenotype similar to promyelocytic-like 
suppressive cells induced in-vitro from healthy bone marrow using a cocktail of GM-CSF and G-
CSF78.   
The expansion of a number of MDSC phenotypes has been described in cancer patients, all of 
them falling in one of the three above mentioned categories and showed in Figure 2. This result 
depends on the lack of a standard maker combination to define human MDSCs, which led to 
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different combinations of common myeloid markers to define myeloid cells populations as 
MDSCs. It is tempting to speculate that some of the subsets are partially or completely overlapping 
inside each category, but so far this possibility has never been proved. This situation is further 
complicated by the plasticity of MDSCs which can express also other markers (like S100A8, 
S100A9, CD79) in response to the tumor-derived factors to which they are exposed (reviewed in 
63). Hence, the definition of human MDSC phenotype is an issue that must find a correct answer, 
also in view of the potential role of these cells as biomarker of response to cancer treatment. To 
address this problem, the Cancer Immunoguiding Program recently organised an international 
proficiency panel to harmonize the immunophenotyping of circulating human MDSC using 
cryopreserved samples.  
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Figure 2: Overview of described human MDSC phenotypes in cancer patients  
The main MDSCs subsets reported in literature were classified as monocytic, granulocytic and 
immature and further divided on the basis of their phenotype. (Solito et al., Annals of the New York 
Academy of Science, 2014) 
Overview of the suppressive mechanisms of human MDSCs 
It has been demonstrated that MDSCs are only capable to suppress the T cell response but also of 
influencing the behaviour of other immune players, like NK  cells, in the context of a cross-talk 
between myeloid cells and cancer (reviewed in 25). Besides, recent studies recognise that MDSCs 
have pleyotropic functions that are not limited to the immune suppression because, these cells 
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are involved also in the metastatic process79, in angiogenesis80 and in the interplay with cancer 
stem cells81. In particular, MDSCs support metastasis development in different ways: they prepare 
the pre-metastatic niche by creating an immune suppressed milieu82 and by re-arranging the 
architecture of extracellular matrix through secretion of metalloproteinase 980,83, but they also 
exert a more direct influence on the metastatic potential of cancer cells inducing the epithelial-
mesenchimal transition84. 
Concerning the immune-suppressive potential, one of their main task is to deprive the tumor 
micro-environment of essential amino acids, like L-arginine or L-tryptophan, through activation of 
Arginase-1 (Arg-1), inducible Nitric Oxide Synthase (iNOS) or Indolamine-2,3-Dyoxigenase (IDO), 
respectively (reviewed in 85). L-arginine depletion reduced the expression of the  chain of T cell 
receptor thus limiting the proliferation of activated T cells86; on the other hand, an altered L-
tryptophan metabolism leads to L-kynurenine production and activation of a down-stream 
pathway that is responsible for induction of regulatory T cells. Another important function is to 
induce an oxidative stress through a coordinated activation of Arg-1, iNOS and NADPH oxydase 
that leads to production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
which hamper the correct function of T cell receptor, block proliferation of T lymphocytes and 
alter the trafficking of these cells (reviewed in 60,63). A third mechanism of immune suppression is 
the direct activation and expansion of regulatory T cells triggered by IL-10 production, activation 
of tolerogenic pathways, like the L-kynurenine pathway, and ligand-dependent interactions25. 
MDSCs are also able to convert Th17 cells into regulatory T cells through a mechanism that is 
dependent on TGF-secretion and retinoic acid87.  
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Figure 3: Principal pathways involved in immune suppression by MDSCs 
Main mechanisms of suppression induced by MDSCs. a) MDSC induce regulatory T cells b) MDSCs 
starve T cells of amino acids that are essential for their growth and differentiation. c) MDSCs induce 
an oxidative stress through production of ROS and RNS. d) MDSC interfere with T cell migration and 
viability and they cross-talk with different immune players. (adapted from Gabrilovich et al., Nature 
Review Immunology, 2012) 
MDSCs are predictors of the clinical evolution of cancer 
Given the pivotal role exerted by MDSCs in the process of immune escape, it is reasonable to 
conceive a relationship between the expansion of these cells and the clinical evolution of cancer. 
Indeed, the frequency of circulating MDSCs has been frequently correlated with the stage of 
different solid tumors63,87-89 and with the level of circulating tumor cells78. Besides, it has been 
demonstrated that MDSC levels are significantly decreased after tumor excision thus proving a 
direct association between tumor burden and the presence of these cells_ENREF_8889-92. As the 
frequencies of circulating MDSCs reflect tumor progression, they constitute a good predictor of 
survival or time-to-progression (reviewed in63). This correspondence was also used to predict 
response to chemotherapy77,78,93 and the study by Walter et al., was the first to demonstrate a 
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correlation between circulating MDSCs and response to a tumor vaccine94. In this study, renal cell 
carcinoma (RCC) patients were treated with a multipeptide vaccination protocol preceded by a 
single-dose cyclophosphamide and six MDSCs subsets were monitored by flow cytometry: RCC 
patients expanded 5 out of six MDSC subsets at baseline and, of note, two MDSC populations 
significantly correlated with survival after vaccination94. Recently, several efforts have been made 
to find reliable biomarkers of response following immune checkpoint blockade treatment. A 
number of parameter were screened but, apart from lymphocytes count, the only promising 
biomarker is the circulating level of MDSCs (reviewed in 95). Indeed, in this context the levels of 
MDSCs can have a double prognostic significance: on one side they reflect the tumor burden while, 
on the other hand, they can be considered as an index of the degree of immune suppression that 
counteracts T-cell activation triggered by ipilimumab.  
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Melanoma 
Epidemiology, pathogenesis and staging 
Melanoma is a skin cancer derived from the malignant transformation of melanocytes, the 
pigmented cells of the skin96. Albeit it accounts only for the 4% of total skin cancers, with 76.000 
new diagnosis in 2014 according to the American Society of Cancer, it is characterised by high 
mortality (American Cancer Society) and is indeed responsible for the 80% of deaths from skin 
cancer and the 5-year survival is about 14%.  
Melanoma is characterised by a stepwise mechanism of carcinogenesis in which each 
transforming event is characterized by defined genetic changes96. Indeed, the genetic instability 
of melanoma is characterised by a set of defined alterations, which could be targeted by specific 
inhibitors, and a multitude of random mutations that are peculiar of each patients and could give 
rise to a plethora of new epitopes recognised by TIL. Indeed the first protocol of adoptive cell 
therapy designed by Rosenberg have been carried out using TILs49. Melanoma carcinogenesis is 
divided in five steps by Clark according to histological changes which could be related to particular 
genetic mutations97 (reviewed in 96) (Figure 4). In the first step a benign nevus, composed of 
melanocytes, grows stimulated by a constitutive activation of the mytogen-activated protein 
kinases (MAPK) cascade, often resulting from mutation of the BRAF gene. The presence of nevi is 
considered benign as long as their growth is controlled by onco-suppressor genes like PTEN and 
CDKN2A, but when mutations occur at this site, the negative regulation is lost and a pre-malignant 
lesion develops (dysplastic nevus). Further progression of the dysplastic nevus is associated with 
decreased differentiation of cancer cells into melanocytes regulated by an oncogene: the 
microphtalmia-associated transcription factor (MITF). The last steps of carcinogenesis are 
characterised by enhanced motility of malignant cells, which start a vertical growth phase invading 
the dermis and progressively spreading to the whole body as metastatic lesions. The major 
alterations present in this phase affect genes involved in shaping the architecture of the tumor or 
coding for adhesion molecules and matrix metalloproteinases.  
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Figure 4: Molecular and biological changes occurring during oncogenesis of melanoma 
Main biologic events, according to Clark’s model, and molecular changes in the progression of 
melanoma. (adapted from Miller et al., New England Journal of Medicine, 2006) 
Melanomas are classified in four stages according to the TNM categories defined by the American 
Joint Committee on Cancer98. The biological parameters considered for the staging procedure are: 
the thickness, the ulceration and the mitotic rate of the primary lesion (T), the number and the 
burden of metastatic lymph nodes (N), the presence of distant metastasis and the levels of serum 
lactate dehydrogenase (LDH) (M). Stage I and II melanoma are characterised by lesions with 
different degree of thickness and ulceration but strictly confined to the skin, while stage III 
melanoma present metastasis to one or more lymph nodes. Stage IV melanoma, which is called 
also metastatic melanoma, is indeed characterised by presence of distant metastasis; the 
localization of the metastasis defined the sub-groups: M1a distant metastasis confined to skin or 
lymph nodes, M1b lung metastasis, M1c all other visceral metastasis with normal LDH levels or 
any distant metastasis combined with elevated LDH.  
Immunological features of melanoma patients 
As described above, TIL could be isolated and manipulated to destroy cancer cells, and 
interestingly, the efficacy of ACT using natural occurring TIL was first demonstrated in 
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melanoma49. Besides, the high genetic instability of melanoma could create a variety of new 
epitopes which may drive the activation of a higher number of TIL endowed with wider specificity 
and affinity for tumor antigens48,99,100. In fact, a variety of antigens have been identified on the 
surface of melanoma cells and they can be classified in three main groups: i) germ cell antigens 
like NY-ESO-1 and MAGE-1 which are normally expressed in male germ cells and silenced in 
somatic cells but re-expressed on malignant melanocytes; ii) differentiation antigens that 
characterised both normal ad melanoma cells and include tyrosinase, melan-A MART-1  and 
gangliosides; iii) unique antigens stemming from random mutations in melanoma cells (reviewed 
in 101). The exposure of these tumor-antigens on melanoma cell surface depends on the genetic 
background of each cancer, and it is thus important to design personalised approaches of 
immunotherapy like ACT with autologous TIL or vaccination with dendritic cells pulsed with a 
lysate of autologous tumor48.  
Despite the evidence that immune effectors can play a significant role in controlling tumor growth 
both spontaneously or in response to therapeutic manipulation , it is clear that in most 
circumstances cancer cells survive their attack as the disease progresses. Several mechanisms 
underlying immune escape have been proposed in melanoma and they induce structural and 
functional changes both in tumor and stromal cells (reviewed in 102).  On one hand, melanoma 
cells become less immunogenic due to down-regulation of antigen exposure or absence of co-
stimulatory molecules, and on the other side they attract suppressive leukocytes through a 
pattern of secreted chemokines and cytokines. In particular, increasing Treg cells infiltration was 
found in nevi during melanocytes’transformation, suggesting that these cells induce 
immunotolerance early during melanoma evolution. Moreover, tumor Ag-specific Treg were 
found in the blood of patients with metastatic melanoma, and they produced IL-10 and 
suppressed T-cell responses in a cell contact-dependent manner.  
In addition, melanoma is characterised also by infiltration of innate cells, like macrophages, 
neutrophils and plasmacytoid DCs, all endowed with suppressive and tumor-promoting functions 
(reviewed in 103). Moreover, several studies reported an expansion of circulating MDSC in 
melanoma patients, and melanoma cells can induce MDSCs from monocytes of healthy donors in-
vitro104. CD14+/HLA-DRlow/- was the first phenotype associated to MDSC expansion in melanoma 
and the suppressive activity of CD14+/HLA-DRlow/- cells on T cell proliferation was dependent on 
transforming growth factor . Subsequent studies demonstrated that ex-vivo derived 
CD14+/HLA-DRlow/- MDSCs induced Treg105 and activated Arg-1 and STAT-3, two important factors 
driving MDSC suppression106. Besides, in a recent publication, we demonstrated that IL4R, which 
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is not only a phenotypic but also a functional marker of murine MDSCs69,71, was expressed on 
human monocytes endowed with suppressive activity, suggesting that IL4R could be a valuable 
marker also for human MDSCs70. Moreover, also granulocytes separated from melanoma patients 
showed a significant up-regulation of IL4R, though the presence of these cells did not correlate 
with a suppressive phenotype.  
Melanoma often matched with induction of systemic inflammation,and indeed the levels of acute 
phase proteins, like C-reactive protein, or inflammatory mediators like IL-6 are strong predictors 
of survival in melanoma patients102,107,108.  
Serum proteins as biomarkers of melanoma 
Biomarkers are tumour- or host-related factors that could be easily measured, i.e. in the serum, 
and are associated with tumour behaviour and patient prognosis. A good number of proteins 
present in the serum of melanoma patients have been correlated with tumor burden or survival 
and they are often used as early biomarkers for recurrence (reviewed in 109). The strongest 
predictors of tumor burden and survival are LDH and S100B levels110.  
The first evidence of correlation between serum LDH levels and prognosis of melanoma dated 
back to 1954 and several studies confirmed this finding109. LDH is a sensible indicator of liver 
metastasis111 and  it is particularly useful to discriminate between patients with better or worse 
prognosis in the metastatic disease. For these reasons LDH is the only serum protein included as 
parameter for melanoma staging by the American Joint Committee on Cancer98.  
S100B belongs to a class of calcium-dependent proteins that are involved in signal transduction 
via inhibition of protein phosphorylation, regulation of enzyme activity and calcium homeostasis 
(reviewed in 112). In-vitro studies demonstrated that S100B inhibits calcium-dependent 
phosphorylation of p53, resulting in impaired function of this protein and a consequent 
uncontrolled tumor growth113. S100 proteins could also exert extracellular function by binding to 
their receptor RAGE, but the direct consequences of this interaction are still under investigation114. 
The association between levels of S100B and melanoma are  known since 1980115, but a recent 
retrospective study on 670 patients with metastatic melanoma clearly identified this protein as a 
marker of tumor burden and as a predictor of survival116. Recently, a multivariate analysis on more 
than 1100 patients with advanced melanoma demonstrated that LDH and S100B are strong 
independent predictive markers for survival in these patients110.  
Proteins involved in inflammatory processes like VEGF, C-reactive protein and IL-6 have been 
recently identified as additional biomarkers of melanoma progression.  
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C-reactive protein (CRP) is an acute-phase factor produced by the liver under a variety of 
inflammatory and stressing conditions including cancer117. Elevated cytokines levels, and in 
particular IL-6, increase CRP production118 and indeed, Tartour et al. investigated the possible 
correlations between IL-6, CRP levels and survival in melanoma patients treated with IL-2119. A 
trend towards association between IL-6 and CRP was observed and both parameters correlated 
with patients outcome. These data were further confirmed in a larger cohort where only CRP 
results to be an independent predictive factor for reduced survival120. The association between 
elevated levels of CRP and negative prognosis was confirmed by Allin et al. in a large prospective 
study including patients with different types of cancer and healthy donors108. The long follow-up 
phase, characterising this project, permits to highlight also a direct association between elevated 
baseline CRP levels in healthy individuals and increased risk of developing different types of 
cancer.  
Interleukin-6 (IL-6) is type 2 inflammatory cytokine whose de-regulation plays a major role in 
inflammatory-associated diseases like autoimmune arthritis121. Studies on melanoma cell lines 
indicated that IL-6 is a negative regulator of primary melanomas whereas it stimulates the 
proliferation of melanoma cells isolated from metastatic disease122. Indeed, high levels of IL-6 have 
been extensively correlated with tumor burden and metastasis in melanoma patients107 and 
Mouawad et al. showed that low IL-6 levels were associated with control of the disease and 
response to a therapeutic regimen based on cisplatin, IL-2 and IFN-.  
Melanoma treatment 
The recommended treatment for melanoma depends on the stage of the tumor: the preferred 
option for early stage melanoma is surgery, possibly combined with adjuvant regimen, while a 
more aggressive approach, including systemic chemotherapy, radiotherapy and immunotherapy, 
is necessary for the management of advanced disease.   
First line therapy for early stage melanoma includes surgical excision of the primary lesion, and 
complete lymphadenectomy recommended in the presence of metastasis to the lymph nodes.  
(reviewed in 124). High risk patients often undergo also adjuvant therapy following surgical 
resection to minimise the risk of recurrence. If surgery and adjuvant regimens are effective for 
control of primary melanomas, the scenario becomes much more complex when patients 
presented with metastatic disease.  
Interferon 2b (IFN2b) was the first agent to significantly improve the OS of metastatic 
melanoma patients125. The mechanism of action of this cytokine is not completely understood. 
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The examination of tumor biopsies taken before and after therapy with IFN2b demonstrated an 
enrichment in the infiltration of T lymphocytes and dendritic cells in the tumors, thus suggesting 
an immunological mechanism of action for this therapy126. For a long period several strategies 
aimed at improving an immune rejection of melanoma have been pursued with contrasting 
results. Indeed, vaccination and adoptive cell therapy with autologous TILs have demonstrated 
some clinical benefit but the only immunotherapeutic regimen approved until 2011 was the 
administration of high doses of IL-2 (reviewed in 124). This cytokine acts sustaining T cell 
proliferation but its efficacy is limited to highly selected patients and it comes at the cost of high 
toxicity. High dose IL-2 is currently approved only for the treatment of metastatic melanoma, 
although it is a treatment given only in specialized and experienced centers.  
Regarding chemotherapy, the alkylating agent dacarbazine, and its oral-available pro-drug 
temozolomide, are the only chemotherapeutic drugs approved for the treatment of metastatic 
melanoma (reviewed in 124). However, only 10-15% of patients treated with dacarbazine 
experienced tumor regression, but this response does not increase OS 127. Different combinatorial 
regimens have been tested to improve the efficacy of chemotherapy in melanoma, but with 
negligible benefits in terms of survival and displaying  higher toxicity.  
Chemotherapy is considered harmful for the immune system and it is well known that 
myelosuppression is one of the most frequent side effect of chemotherapeutic drugs. However, a 
number of studies, mostly in mouse models, suggest that conventional chemotherapy could 
improve immune-rejection of the tumors by inducing immunogenic cell death (ICD) of malignant 
cells (reviewed in 128). ICD is characterised by alterations in the composition of the plasma 
membrane of dying cells and by the release of specific transductors of immunogenic signals that 
promote engulfment of dying cells, presentation of tumor antigens, and production of pro-
inflammatory cytokines by dendritic cells, thus boosting anti-tumor response129. A similar 
induction of ICD was seen also upon administration of radiotherapy in pre-clinical models of 
melanoma130 or upon infection with oncolytic-virus in humans131. Another possible synergy 
between chemotherapy and immune-rejection is the activation of genes involved in the immune 
response and leukocyte activation following dacarbazine administration which was demonstrated 
to improve the response to Melan-A vaccination132.   
Another possible synergic effect on tumor eradication can be achieved by combination of 
chemotherapy and immunotherapy which on one side directly kills cancer cells and on the other 
side activates the suppressed immune system to mount a robust anti-tumor response (reviewed 
in 133). Early reports have suggested that chemotherapeutic agents administered in combination 
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with IL-2 or IFN can improve the response rate in melanoma patients134,135, but an overview of 18 
studies comparing standard chemotherapy to chemoimmunotherapy demonstrated that the 
increased response rate did not translate into a survival benefits for these patients136. However, 
the introduction of ICI opens the way for new combinatorial strategies, in particular for patients 
with brain metastasis who showed an increased overall response rate when treated with the 
combination of ipilimumab and fotemustine137 (reviewed in39).  
The improved knowledge of the genetic instability of melanoma and the progress of tumor 
immunology led to a revolution in the management of melanoma which results in the approval of 
two new class of drugs for the treatment of metastatic melanoma by FDA in 2011 (reviewed in138). 
The discovery of the activating mutations in the MAPK pathway, which promote uncontrolled 
proliferation of melanocytes, set the basis for the approval of sorafenib, a non-selective BRAF 
inhibitor. Unfortunately this drug failed to show any benefit139-141, but when specific inhibitors for 
the kinases involved in the MAPK pathway entered into clinical trials, they showed extremely 
promising results (reviewed in 138). Two BRAF inhibitors, dabrafenib and vemurafenib and one MEK 
inhibitor, trametinib showed significant effects in terms of tumor regression compared to 
dacarbazine. The toxicity profile of these drugs is milder than classical chemotherapy but the 
kinetics of response is characterised by high initial tumor response followed by development of 
resistance at a median of five to seven months. The second class of drugs that contributes to the 
therapeutic revolution in the field of metastatic melanoma is that of immune checkpoint 
inhibitors39. These drugs are monoclonal antibodies inhibiting key negative regulators of T cell 
activation like Cytotoxic T cell antigen 4 (CTLA-4) and Programmed Death 1 (PD-1). They act 
releasing the brake on T cells exerted by the suppressive network active at the tumor site, and 
therefore enhance the probability of tumor-specific T cells to attack the malignant clones. At 
present time, two ICI have been approved by the FDA for the treatment of metastatic melanoma: 
ipilimumab and pembrolizumab which are targeted to CTLA-4 and PD-1, respectively. These drugs 
are characterised by a low rate and a delayed onset-time of response, but also longer duration of 
the clinical benefits in responding patients. The encouraging data from clinical studies indicate 
that a combination of targeted therapy with BRAF or MEK inhibitors and ICI could feasibly maintain 
the high frequency of response typical of targeted therapy and prolonged the control of the 
disease in patients responding also to the immunotherapy approach.  
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Ipilimumab: a novel immune checkpoint inhibitor for the treatment of 
metastatic melanoma  
The biology of immune checkpoints 
T cell response starts with the recognition by T cell receptor (TCR) of the peptide-major 
hystocompatibility complex (MHC) on APC but this event is not sufficient for full activation of T 
cells. Indeed, the magnitude and the quality of T cell response depend on the integration between 
signals deriving from co-stimulatory and co-inhibitory receptors, expressed by the lymphocyte and 
known as immune checkpoints molecules16. In physiological conditions, immune checkpoints are 
crucial for maintaining self-tolerance and to prevent hyper-activation of adaptive response 
towards pathogens which could eventually damage the surrounding tissues (reviewed in40). 
Positive regulators of T cell response include ICOS, CD137 and CD28, the master positive regulator 
of T cell activation; in contrast, several negative regulators have been described: CTLA-4, PD-1, 
LAG-3, Tim-3, BTLA, A2aR (Figure 5). Amplification of signalling through inhibitory receptors 
participating to immune checkpoint is a useful strategy for the treatment of autoimmune arthritis 
and transplant rejection142. However, a wider field of application was found for mAb blocking 
these inhibitory immune checkpoint molecules for cancer treatment (reviewed in43). In fact, the 
expression of inhibitory immune checkpoints could be deregulated by tumors and their blockade 
unleash the potential of anti-tumor responses. Several immune checkpoint molecules represents 
promising targets for therapeutics, but, at the moment, only two ICI have been approved by the 
FDA for treatment of metastatic melanoma: ipilimumab and pembrolizumab, which are directed 
to CTLA-4 and PD-1 , respectively41,42.   
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Figure 5: Immune checkpoint molecules regulate T cell responses 
Multiple ligand-receptor interactions between T cells and APCs convey co-stimulatoy and co-
inhibitory signals are known as  immune checkpoints. A T cell response is initiated following antigen 
recognition by T cell receptor (Signal 1), but the onset of T cell response results from the balance of 
stimulatory and inhibitory signals delivered by immune checkpoint molecules. (Pardoll et al., Nature 
Review Cancer 2012) 
CTLA-4 is a key negative regulator of T cell activation, opposed to the stimulatory receptor CD28143 
(Figure 6). CTLA-4 is mainly expressed on T cells after activation143,144, while Treg have a 
constitutive expression of this marker due to positive regulation of CTLA-4 expression by the Treg-
associated transcription factor FoxP3145. Indeed, it has been demonstrated that CTLA-4 
participates to the suppressive function of Tregs146,147. CTLA-4 presents a complex trafficking 
behaviour: conventional T cells store CTLA-4 in cytoplasmic vescicles and TCR stimulation 
promotes its exposure on the cell surface144; however, CTLA-4 is also repetitively endocytosed by 
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T cells with the result that only a small fraction of the CTLA-4 pool is exposed on the cell surface148. 
For a long time, expression of CTLA-4 was thought to be confined on T cells but recent reports 
described its expression also on myeloid cells149,150 and tumors151, albeit its functional role on 
these cells remained largely unknown. In contrast, a large number of mechanisms have been 
proposed that account for the inhibitory activity of CTLA-4 towards T cell activation and they 
consist of both cell-intrinsic and cell-extrinsic pathways (reviewed in 152). Cell-intrinsic pathways 
include all functional mechanisms acting on the cell that express CTLA-4, namely T cells, while cell-
extrinsic pathways are those in which CTLA-4 carries out its effects through other cells. The most 
important mechanism of action of CTLA-4 blockade lays in the inhibition of the co-stimulatory 
signal delivered by CD28 to T lymphocytes upon TCR engagement143. Indeed, CTLA-4  competes 
with CD28 for binding to their common ligands, CD80 and CD86,  expressed by APC153 and, since 
CTLA-4 possesses a higher affinity for the ligands than CD28, the inhibition is efficient and stable; 
recent reports demonstrated that CTLA-4 can also physically remove CD80 and CD86 form APC 
resulting in a further elongation of CD28 blockade154. In addition, CTLA-4 can oppose the co-
stimulatory effect of CD28 also by delivering an intra-cellular inhibitory signal to T cell, thus 
decreasing the phosphorylation of several key proteins in the TCR signalling cascade155,156. 
 
Figure 6: Ipilimumab blocks negative signaling from CTLA-4 
A) T cells requires two signals for full activation: the first signal is delivered by the T cell receptor 
(TCR) while the second involves co-stimulation through the interaction of CD28 on T cells with B7 
molecules (CD80, CD86) on APCs. B) upon T-cell activation, CTLA-4 is recruited to the plasma 
membrane and, binding with higher affinity than CD28 to B7 molecules, it delivers an inhibitory signal 
that block T cell activation. C) ipilimumab blocks CTLA-4 cell-intrinsic and cell-estrinsic functions, thus 
releasing the brake on T cell activation. (Postow et al., Clinical Cancer Res 2012) 
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PD-1 is another negative regulator of T cell function whose blockade has been exploited for cancer 
treatment. Similar to CTLA-4, also PD-1 expression is induced upon activation on T cell surface157 
and its expression is elevated in circulating T lymphocytes from patients with chronic infection, 
like HIV, and cancer158-160. As expected, PD-1 is mostly expressed by antigen-experienced cells 
belonging to the memory compartment159 and further up-regulated when memory T cells enter 
the effector phase161. Evidence of PD-1 expression have been observed also on Treg162. PD-1 can 
bind to PDL-1 and PDL-2 which could be expressed by myeloid cells and tumors (reviewed in163). 
In the tumor microenvironment, the major PD-1 ligand that is expressed is PDL-1164 (reviewed in 
163) and its expression could be further up-regulated by IFN-. In contrast to CTLA-4 that blocks 
T cell activation at the time of antigen exposure in secondary lymphoid organs, the major role for 
PD-1 have been observed in the periphery where it limits the effector functions of previously 
activated T cells (reviewed in40). In this context, PD-1 acts by modifying the duration of T cell-APC 
contact166, by inducing a functional impairment called T cell exhaustion21 and by enhancing the 
proliferation of Treg162.  
In the last years, ipilimumab and pembrolizumab, two mAb targeting CTLA-4 and PD-1, 
respectively, have been introduced for melanoma treatment. These immune checkpoint inhibitors 
were the first treatment demonstrating a significant increase in the survival of stage IV melanoma 
patients41,42. As both drugs rescue T cell activation at different levels (ipilimumab mainly by 
counteracting CD28 signalling and by reducing Tregs, while pembrolizumab by inhibiting 
exhaustion of CD8+ T cells), clinical approaches of combination are currently under investigation. 
Ipilimumab: from pre-clinical model to the clinical practice  
Ipilimumab is a fully human IgG1 mAb approved for the treatment of metastatic melanoma at the 
dose of 3mg/kg. It was approved in the United States in 2011 and in Europe in 2012. Evidence 
from preclinical models indicated that ipilimumab monotherapy was safe and effective in rejecting 
a large number of transplantable tumors, in particular in mice with low tumor burden and 
transplanted with cell lines that were historically considered immunogenic167. This result is not 
surprising considering the pharmacodynamics of ICI; indeed, these drugs can revert suppression 
of an existing anti-tumor immunity but they are not able to generate an ex-novo immune response 
towards cancer. However, subsequent studies indicated that in case of poorly immunogenic 
tumors, the combination of ICI and vaccination is a feasible and effective option168 to establish an 
effective anti-tumor response.  
During clinical development, phase II studies with escalating dose and different schedule of 
treatment lead to the determination of the minimum effective dose characterised by acceptable 
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toxicity, that is 3mg/kg (reviewed in 169). In phase III studies ipilimumab treatment produced a 
significant advance in terms of OS compared to a vaccination strategy with gp100 vaccine41 and 
to dacarbazine, the standard chemotherapeutic regimen for melanoma170. Four pattern of tumor 
response to ipilimumab were noted: i) immediate tumor regression in baseline lesions without 
development of new lesions, ii)durable stable disease followed by slow reduction of tumor 
burden, iii) response in the presence of new lesions and iv) response following an increase in total 
tumor burden171. Histological studies revealed that edema or leukocyte infiltration accounted for 
the apparent increased volume of some lesion in responding patients. Given this peculiar pattern 
of response, that differs from that of standard chemotherapy, new immune-related criteria were 
defined for assessment of disease progression following ICI treatment. Treatment with ipilimumab 
was typically associated with the onset of irADR which were strongly related to its immune-based 
mechanism of action. The onset of irADR was common and an incidence of 64% was reported in a 
pooled analysis of 14 studies evaluating various doses of ipilimumab172. According to this study, 
the irADR were tipically manageable, but about 20% of patients developed serious toxicity which 
required a prompt management by expert clinical oncologists.  Most of immune-mediated irADR  
involved mainly the skin, the gastrointestinal mucosa, the liver and the endocrine system 
(reviewed in173). While the onset of rash, diarrhea and colitis can be rapid but readily resolved 
with administration of glucocorticoids, endocrine irADR were more severe and, in some cases, life 
threatening.  
Biomarkers for immune checkpoint inhibitors 
The introduction of ipilimumab in the clinical practice was welcomed with enthusiasm by clinical 
oncologists and the subsequent approval of pembrolizumab has open new options for 
therapeutics. In the next years the opportunity to have different ICI on the market will bring about 
the need for definition of which immune checkpoint pathway is more active, and thus constitute 
a better target, in each patient. Moreover, ipilimumab, as single agent, produces log-term benefits 
in about 12% to 49% of patients39,174 and this response comes at the cost of a toxicity profile that 
can be serious and a consistent economic burden for the health care system173. Hence, there is an 
urgent need for predictive biomarker that can guide clinical oncologist in the selection of patients 
that have a higher probability to respond to ipilimumab and to direct other patients to alternative 
therapeutic strategies. Given the multiple cell-intrinsic and cell-extrinsic mechanisms of action of 
CTLA-4, the search for predictive biomarkers involves a large number of immune players and 
tumor-related factors in particular T lymphocytes, myeloid cells, serum proteins and the genetics 
of the tumor.  
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Only few studies identified baseline parameters predictive of survival or response to ipilimumab, 
here named predictive biomarker, while a larger number of factors, associated with the 
mechanism of action of ipilimumab, can predict patient’s prognosis when assessed after 
treatment; these markers will be named early response marker to distinguish them from 
predictive biomarkers (reviewed in 175).   
An overview of the studies identifying predictive biomarkers indicate that patients with higher 
probability to benefit from ipilimumab treatment are those presenting an active immune system 
with low frequencies of MDSCs176 and high absolute lymphocyte count177-179. In this context, the 
presence of humoral and cellular responses to NY-ESO-1 was correlated with OS in ipilimumab-
treated patients, and this parameter may help the identification of patients with an existing anti-
tumor immunity which in turns have more probability to respond to ipilimumab180,181. Recent 
studies performing gene expression profiling on melanoma biopsies from patients undergoing 
ipilimumab treatment revealed that clinical response was associated with a Th1 signature and 
expression of IFN- inducible genes at baseline182; in addition, the Th1-associated markers were 
further up-regulated after the treatment182. However, conflicting results came from another study 
in which clinical response to ipilimumab was correlated with high baseline expression of FoxP3 
and IDO, genes typically associated with suppressive populations183. Two recent studies pointed 
out that immune rejection of cancer in response to ICI is antigen-specific both in humans and in 
mice, and the antigenic drivers of this process are mutant neo-epitopes arising from the genetic 
instability of tumors99,100. One of these studies deals with melanoma patients, and authors 
brilliantly demonstrated that this mutant immunologic signature was predictive of response to 
the treatment and the neo-epitopes, composing this signature, were homologous to known viral 
and bacterial antigens that T cells are likely to recognize100.   
In addition to immunological parameters, low tumor burden (indicated by levels of LDH and S100B 
below the upper limit of normal)179,  low serum VEGF178 and low levels of inflammatory indexes 
(like C-reactive protein and erythrocyte sedimentation rate)177,179 are also predictive of improved 
OS following ipilimumab treatment. Gene expression profiling of melanoma biopsies indicated 
that expression of melanoma-associated genes (NY-ESO-1, MAGE-A, MELAN-A, TYR) and cell 
signalling molecules involved in tumorigenesis are reduced in in post-treatment biopsies of 
responding patients182.  
A large number of studies identified immunological and tumor-related parameters as early 
response markers. Overall activation of T cells was seen in responding patients with increased 
expression of T cell activation markers (ICOS184-186, Ki67185, HLA-DR187), increased number of 
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circulating177-179,188 and TIL183, expansion of the central memory subset187 and increased 
phosphorylation of effector molecules down-stream to TCR signalling189. Only a minority of studies 
confirmed T cell activation by functional studies, although Ipilimumab was shown to increase the 
response to melanoma antigens181,187 and the humoral immunity following vaccination against 
influenza and pneumococcus187. Since Treg express CTLA-4 constitutively, it is reasonable to argue 
for Treg depletion via antibody-dependent cell-mediated cytotoxicity following administration of 
anti-CTLA-4 antibodies; however, conflicting results were observed concerning modulation of Treg 
by ipilimumab. Indeed, some authors reported that increasing frequency of circulating Treg 
correlates with an improved progression-free survival181, while others observed a marked 
reduction of the levels of Treg in patients with longer survival or clinical response to 
ipilimumab177,190. The same controversial trend was observed also for tumor-infiltrating Treg181,183. 
In contrast, the monitoring of circulating MDSCs produced more homogeneous results with 
several authors indicating a strong correlation between reduced frequencies of monocytic, 
granulocytic and immature MDSCs and improved response or survival following ipilimumab 
treatment176,181,191.  
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Technical issues on biomarkers development 
A relevant issue related to the immunomonitoring of patients undergoing ICI therapy is the 
increasing need to compare parallel biomarker datasets generated in different laboratories 
(reviewed in175). Indeed, many efforts have been made to identify possible predictive biomarkers 
and early response markers for ipilimumab but, the results are of difficult interpretation since 
standardized reference interval are not available for most of immunological markers. Hence, since 
standardization of assays across laboratories is often difficult to achieve, an alternative approach 
is assay-harmonization. Organization of proficiency panels joined by a large number of 
experienced laboratories is a common strategy for assay harmonization. The aim of proficiency 
panels is to identify a set of parameters impacting on variance of a certain assay and subsequently 
find a consensus on a list of mandatory, harmonized parameters to be applied to single-laboratory 
protocols in order to generate comparable results. The Cancer Imunoguiding Program, a European 
network of leading scientists in the field of immunology, is the sponsor of a variety of proficiency 
panels to harmonize immunological assay like: ELISPOT, tetramer staining, intracellular cytokines 
staining or immunophenotyping of circulating MDSCs192-194. Another important target for 
immunomonitoring of cancer patients is the development of guidelines for a uniform report of 
the results. Indeed, this is a key step for sharing results with collaborating laboratories and, 
subsequently, for the integration of multiple datasets. The Minimal Information about T cell Assay 
(MIATA) project, developed by a large number of leading scientists195, and the Minimum 
Information about a Flow Cytometry Experiment, developed by International Society for 
Advancement of Cytometry196, are projects along this line of research.  
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AIM OF THE STUDY 
Ipilimumab, an antibody that blocks the function of the immune checkpoint Cytotoxic T- 
Lymphocytes Antigen-4 (CTLA-4), was the first immunomodulatory antibody approved for the 
treatment of metastatic melanoma. Given its immune-mediated mechanism of action, it is 
important to monitor the immune profile of patients receiving this therapy, to understand the 
mechanisms set in motion by the treatment and to correlate them to the clinical responses. In 
particular, there is a great interest in monitoring suppressive populations able to divert T cell 
functions, and one of the key suppressive players expanded in cancer patients are myeloid-derived 
suppressor cells (MDSCs). The immunophenotyping of MDSCs is performed by multicolour flow 
cytometry and is characterised by a high degree of complexity given the fact that several myeloid 
phenotypes have been described, ranging from immature cells to more differentiated cells such 
as monocytes and granulocytes, and moreover a specific marker of such cells is still missing. At 
present, a uniform methodology for the phenotyping of MDSCs by flow cytometry is missing.  
To overcome this obstacle, our group organised, under the umbrella of the Cancer Immunoguiding 
Program, a proficiency panel to harmonize the phenotypic definition of human MDSCs. The first 
purpose of the panel is to identify a robust markers combination for identification of a number of 
non-overlapping MDSC subsets; the panel also provides individual feedback to each participant 
laboratory in order to guide the harmonization of the experimental procedures used to phenotype 
circulating MDSCs. This combined effort will hopefully drive to a consensus on the minimal 
requirements for MDSC phenotyping that, in turns, will be used as a diagnostic tool to monitor 
MDSCs.  
An interesting application of MDSC phenotyping is the monitoring of these cells in melanoma 
patients undergoing ipilimumab treatment, potentially linking their level to therapy outcomes. 
Indeed, given the relatively recent knowledge of the immunological profile of toxicity, and the 
high cost of ipilimumab treatment, it is of great interest to develop robust predictive biomarkers 
supporting a more rational use of this drug, including the selection of patients with a higher 
probability to respond to the drug. To this end, the present study was designed to collect a wide 
dataset composed of clinical information and of tumor-associated and immunological parameters 
that we analysed using a multivariate non-parametric statistical approach in order to identify the 
parameters useful for implementing the clinical management of patients treated with ipilimumab.   
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MATERIALS AND METHODS 
HARMONIZATION OF IMMUNOPHENOTYPING OF MYELOID-
DERIVED SUPPRESSOR CELLS 
Selection of the donors 
Immunophenotyping of 10 putative subsets of MDSCs was performed on cryopreserved samples 
from three healthy donors (HBC-480, HBC-514, L29_3). The donors were centrally pre-selected by 
the organising committee among a set of PBMC samples derived from leukapheresis of healthy 
donors. All donors gave their informed consent before enrolment. The organising committee 
analysed the PBMC samples from different leukapheresises by flow cytometry and chose the 
donors with the most significant expansion of the 10 putative MDSC subsets. Two vials of each 
donors were then shipped to the participant laboratories in dry-ice and stored in liquid nitrogen 
upon arrival.  
Guidelines for the first step of the proficiency panel  
Experiment guidelines were sent to participants in order to indicate the mandatory parameters 
which must be fulfilled in the first experimental step of the proficiency panel and, as indication, 
exemplary staining cocktails, protocol and gating strategy were provided.  
The proposed staining cocktails contain 7 markers commonly used for MDSC recognition plus a 
dead-cell marker (DCM): HLA-DR, CD14, CD15, CD11b, CD33, Lineage cocktail (defined as 
CD3/14/19/56), CD124. This markers combination allows the identification of 10 myeloid subsets: 
MDSC1 CD14+/CD124+ 70, MDSC2 CD15+/CD124+ 70, MDSC3 Lin-/HLA-DR-/CD33+ 78, MDSC4 
CD14+/HLA-DRlow/- 72, MDSC5 CD15+/CD14-/CD11b+ 74, MDSC6 CD15+/FSClow/SSChigh 197, MDSC7 
CD15-/CD14+/CD33high/HLA-DRlow 198, MDSC8 CD15+/CD33high, MDSC9 CD14-/CD15-/CD33high and 
MDSC10 Lin-/HLA-DRlow/CD11b+ 199. Participants were asked to perform the staining twice, in two 
separate days, in order to calculate intra-laboratory variance. For each donor in each of the two 
experimental runs, participants were asked to determine cell viability, and test and report the 
number of total cells, singlets, monocytes and lymphocytes plus 10 putative MDSC phenotypes 
using one 8-color panel and/or three 4-color flow cytometry panels.  
In addition guidelines indicated to use at least one million PBMCs for tube, not to perform a resting 
period after thawing the cells, and not to fix the stained cells.  
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Each group was asked to perform data analysis using their own gating strategy and to report it in 
single layouts; moreover, groups were asked to determine the absolute number of the requested 
cell populations with or without the presence of a DCM.  
Experimental procedure used by our laboratory 
In addition to panel design, our group was one of the laboratories that participated to the 
proficiency panel. As some parameters were free of choice in the panel’s guidelines, this section 
describes the protocols we chose for staining, acquisition and analysis of the samples.  
We identified the 10 putative MDSC subsets according to all mandatory parameters described in 
the panel’s guidelines. The 8-color staining cocktail used in our laboratory is composed of: anti-
CD11b Alexa 700 (clone ICRF44, BD Pharmingen), anti-CD14 APC-H7 (clone MP9, BD Bioscience), 
anti-CD15 V450 (clone MMA, BD Biosciences), anti-CD33 PECy7 (clone P67.6, BD Biosciences), 
anti-CD124 PE (clone 25463, R&D SYSTEMS), Lineage cocktail (anti-CD3-14-19-56) (clone UCHT1, 
M5E2, HIB19, NCAM16.2, BD Biosciences and BD Pharmingen), anti-HLA-DR APC (clone L243, BD 
Biosciences). The Live/Dead (L/D), an amine-reactive dye, was chosen as DCM because it resists 
to cell-fixation with unaltered staining capability. 
PBMC were thawed at 37°C, then washed in ice-cold IMDM (Gibco) supplemented with 10% 
heath-inactivated fetal bovine serum (FBS) (Gibco), 1% Pen-Strep (Lonza), 1% Hepes (Lonza), 1% 
- Mercaptoethanol, AAG (Asparagine 0.24mM, Arginine 0.55mM, Glutamine 1.5mM) (Sigma-
Aldrich) and spinned at 1300 rpm for 6 minutes at 4°C. Cells were counted using trypan blue to 
exclude dead cells. The viability ranged from 94 to 77% and the yield after thawing ranged from 
37 to 58%.  
In each experimental run we prepared 4 tubes per donor, 3 tubes were used as controls (unstained 
cells, FMO control for HLA-DR and for CD124) while one tube contained the 8-color staining. FMO 
are fluorescence minus one controls, which contain all the antibodies of the staining cocktail with 
the exception of the antibody for which a control is needed200. For each donor, 1x106 PBMCs were 
distributed in each tube, washed with staining buffer and subsequently centrifuged at 1300 rpm 
for 6 min at 4°C. The supernatant was discharged and the cells were resuspended in 25μl of Fc-
Receptor blocking solution (Miltenyi Biotec) and incubated at 4°C for 15 minutes. Then, an 
appropriate quantity of staining buffer was added in order to reach the final volume of 100l. 
Afterwards, anti-CD124 PE antibody was added and incubated at 4°C for 10 minutes. 
Subsequently, a mixture of diluted antibodies (plus L/D) was added to the tubes and incubated at 
4°C for 20 minutes . Anti-HLA-DR was added only in FMO CD124 and MIX tubes. Cells were washed 
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with staining buffer and subsequently centrifuged at 1300 rpm for 6 min at 4°C. The supernatants 
were discharged and cells resuspended in 350μL of staining buffer for immediate acquisition using 
a LSRII flow cytometer (BD Biosciences) equipped with 4 lasers (405nm, 488nm, 561nm, 640nm). 
The staining buffer used was the Hanks' Balanced Salt Solution for Flow Cytometry supplemented 
of 1% FBS: 137mM NaCl (Sigma-Aldrich), 5mM KCl (Sigma-Aldrich), 0.3mM Na2HPO4 (Sigma-
Aldrich), 0.7mM KH2PO4 (Sigma-Aldrich), 0.4mM MgSO4 (Sigma-Aldrich), 0.3mM MgCl2 (Sigma-
Aldrich), 5mM Glucose (Sigma-Aldrich), 4mM NaHCO3 (Sigma-Aldrich), 1mM EDTA (Sigma-
Aldrich). 
We set-up compensation on the base of automated compensation using BD Comp beads and the 
antibodies included in the staining cocktails. L/D was substituted with anti-HLA-DR V500 (BD 
Bioscience). The compensation matrix generated by BD FACS Diva software was manually edited 
to adjust overcompensation wrongly introduced by the software. Data were analyzed using FlowJo 
software (Three Star Inc). 
To identify the 10 putative MDSC subsets, the following gating strategy was adopted: first set-up 
of a morphological gate based on FSC and SSC properties, then exclusion of doublets and dead 
cells (when required) according to the properties of each sample. After these preparative steps, 
the 10 putative MDSC subsets were identified as shown in Figure 1 of the Results. The gate for 
HLA-DRlow/- cells was based on the FMO HLA-DR control performed for each sample. The gate for 
CD14+/CD124+ cells was set-up considering the fluorescence of FMO CD124 and CD14- cells for 
each sample. The same strategy was used for CD15+/CD124+ cells. The gating strategy for MDSC 
identification did not change between analyses with or without exclusion of dead cells. The 
absolute number of all requested populations was reported in a file with or without the dead cell 
marker. 
Central data analysis  
Results from the 23 participating laboratories were centrally collected and analysed. Absolute 
numbers of the 10 putative MDSC subsets were normalized on the count of lymphocytes + 
monocytes. Variance was measured as %CV = (standard deviation/mean)*100. Comparison 
between %CV or normalized frequencies of myeloid subsets of different groups was performed 
using the Wilcoxon Signed-Rank test. Significance level was set for P<0.05.  
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IMMUNOMONITORING OF MELANOMA PATIENTS TREATED WITH 
IPILIMUMAB  
Patients 
Thirty-seven patients with a diagnosis of stage IV melanoma were enrolled in the study. A 
description of the clinical characteristics of these patients is reported in Table 1. Exclusion criteria 
for the administration of ipilimumab were the presence of brain metastases with symptoms or 
requiring treatment and an history of autoimmune disease. Ipilimumab was administered after at 
least another line of treatment, and therefore previous use of systemic chemotherapy, 
radiotherapy or BRAF inhibitors was allowed. 21 age- and gender-matched healthy donors were 
used as controls. The study was approved by the ethical committee of Istituto Oncologico Veneto 
and all the patients enrolled provided a written informed consent before blood withdrawal. 
Patients received four administrations of ipilimumab (3 mg/kg) every three weeks, as approved 
by the Italian Medicine Agency during the registration phase. In case of onset of immune-related 
adverse reactions to the treatment, requiring corticosteroids treatment, the therapy was 
discontinued and eventually resumed when patients recovered from toxicity. Disease progression 
was monitored by computered axial tomography (CAT) 12 weeks after the first infusion of 
ipilimumab and further confirmed with an additional CAT at week 16. Response to the treatment 
was assessed using the immune-related Response Criteria171. Patients presenting stable disease, 
partial and complete response were considered responders, while patients with progressive 
disease were included in the non-responder group. Follow-up of patients continued until disease 
progression and afterwards patients were provided with the best alternative therapeutic 
approach. Patients who presented, at any time within the observation period, immune-related 
adverse drug reactions (irADR) with severity above grade 3 were called ADR+ while patients 
without irADR or with an irADR severity below grade 3 were named ADR-.  
Study design  
Peripheral blood from melanoma patients was collected at baseline (W0) and 12 weeks after the 
first dose of ipilimumab was administered (W12). Additional blood samples were collected from 
patients every twelve weeks until disease progression. Blood samples were withdrawn in EDTA-
treated vacutainer tubes (BD Bioscience) and processed immediately from healthy donors and 
from patients. A set of parameters associated with the immune system and tumor burden were 
monitored at W0 and W12. Circulating levels of myeloid and T cell subsets were evaluated by 
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multicolor flow cytometry, while hematological parameters were evaluated by the Central 
Laboratory of the University Hospital of Padova. All collected parameters are listed in Table 1.  
CLASSIFICATION NAME ABBREVIATION 
HEMATOLOGICAL 
PARAMETERS 
C-reactive protein CRP 
S100B  
Vascular-endothelial growth factor VEGF 
Lactate dehydrogenase LDH 
Interleukin - 6 IL-6 
SUBSETS OF 
MYELOID CELLS 
CD14+/IL4R+ MDSC1  
CD15+/IL4R+ MDSC2  
CD15-/Lin-/HLA-DR- /CD33+ /CD11b+ MDSC3  
CD14+/HLA-DRlow/- MDSC4  
CD15+/V500high/SSChigh Putative eosinophils 
CD15-/Lin-/HLA-DR+/CD33dim Putative dendritic cells (DC) 
T CELL SUBSETS 
CD3+  
CD3+/CD4+  
CD3+/CD8+  
CD3+/CD4+/PD-1+  
CD3+/CD8+/PD-1+  
PD-1+ within CD3+/CD4+  
PD-1+ within CD3+/CD8+  
CLINICAL DATA 
Stage  
Circulating tumor cells CTC 
Eastern Cooperative Oncology Group 
performance status  
ECOG PS 
Number of doses  
Time-to-progression TTP 
Overall survival OS 
Immune-related adverse drug reaction irADR 
 
Table 1: Parameters monitored in melanoma patients  
The table indicates the classification and the abbreviation of each parameter included in the dataset 
used in this study .  
In addition, for each blood sample, plasma and PBMCs of patients and healthy donors were 
cryopreserved. PBMC and plasma were isolated from peripheral blood by density gradient 
centrifugation on Ficoll-Paque PLUS (GE Healthcare-Amersham). Peripheral blood was diluted 1:3 
in PBS, stratified on Ficoll-Paque PLUS and centrifuged 30 minutes at 1800 rpm at 20°C. After 
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centrifugation plasma was collected, centrifuged to discard possible contaminating cells, and 
aliquoted for cryopreservation at -80°C. PBMCs were aspirated, washed 3 times with PBS 1% 
human serum type AB (HS) (LONZA), and stored in liquid nitrogen. 
Characterization of the immune profile by flow cytometry 
The presence of circulating myeloid and T cell subsets was assessed in whole blood samples by 
multi-color flow-cytometry, in order to identify 4 subsets of MDSCs, putative eosinophils and 
dendritic cells (DC) and different subsets of T lymphocytes. The myeloid subsets were identified 
using the staining panel previously reported for the MDSC panel. The staining panel for 
identification of T cell subsets is composed of: anti-CD3 ECD (clone UCHT1, Beckman Coulter), anti-
CD4 FITC (clone SK3, BD Bioscience) anti-CD8 APC-H7 (clone SK1, BD Bioscience), anti-PD-1 PE 
(clone PD1.3.1.3, Miltenyi Biotec). 
For myeloid subsets phenotyping, 150l of fresh blood were washed with staining buffer and 
subsequently incubated with Fc-Receptor Blocking reagent (Miltenyi Biotec) at 4°C for 15 minutes. 
Afterwards, cells were stained with anti-IL4R (anti-CD124) PE antibody and incubated at 4°C for 
10 minutes. Later, the mixture of properly diluted antibodies (plus L/D) was added to the tubes 
and incubated at 4°C for 20 minutes. Cells were then washed with staining buffer and centrifuged 
at 1300 rpm for 6 min at 4°C. For T lymphocytes phenotyping, the procedure was the same with 
the exception that 50l, instead of 150l, of blood were used per tube and the total incubation 
time for antibody-staining was reduced from 30 to 20 minutes. After the washing step, red blood 
cells were lysed using Cal-Lyse whole blood lysing solution (Life Technologies) according to 
manufacturer instructions. Absolute counts of T cell subsets was determined using TruCount tubes 
(BD Bioscience). Data acquisition was performed using a FACSCalibur or a LSRII (Becton Dickinson) 
flow cytometer. Data were analyzed using FlowJo software (Three Star Inc). Autofluorescence, 
FMO controls for HLA-DR, CD124 and PD-1 and isotype control for CD124 were used as negative 
controls. Exemplary gating strategies for phenotyping of myeloid and T cell subsets are shown in 
Figure 5-6-7-9 of the Results section.  
Standardization of the immunophenotyping assay 
To standardize the staining panels for myeloid and T lymphocytes’ subsets, a dilution of 
antibodies that maximize the signal to noise ratio was chosen on the basis of single antibodies 
titration.  
52 
 
In addition, a protocol to monitor the performance of antibodies targeted to HLA-DR and IL4R 
was set-up, by using an EBV-B cell line that constitutively expresses these markers at high 
expression intensity. To reduce inter-assay variance, we used a single batch of B cell-line, fixed 
and permeabilized before cryopreservation. For each staining, the control cell-line was run in 
parallel to blood staining, labelling the cell-line with the same amount of anti-HLA-DR or anti-IL4R 
antibodies used for blood staining (Fig. 1 A). We acquired the control cells before acquiring the 
blood sample, and we could thus determine whether the mean fluorescence intensity (MFI) of 
HLA-DR or IL4R were included in the range of tolerance. The range of tolerance was built by 
repeated staining of the control cells performed before the beginning of the study. To this end, 
we calculated the MFI of HLA-DR and IL4Rof control cells in repeated measurements and we set 
the borders of tolerance within the mean ± 2x standard deviation of our measures (Fig. 1 B). 
 
Figure 1: Standardization of antibody performance 
Panel A shows a representative HLA-DR staining on reference B cell-line. Panel B reports the MFI 
values for reference B cell-line in independent experiments (black dot n=23), the tolerance range (red 
lines) and the 10th and 90th percentile of the measures (blue lines). Results describing the trend of 
HLA-DR and IL4R MFI are reported in the left and right plots of panel B, respectively.  
Another source of experimental variation might be the performance of the flow-cytometer. We 
weekly check the performance of the flow cytometer using the automatic protocol provided by 
Diva software. In addition, to assess the potential variation of the performance of the flow 
cytometer, we monitored the performance of the instrument during every experiment using a 
protocol after Perfetto et al. 201. A pool of commercial fluorescent particles was used and a 
tolerance range was defined on the basis of the MFI of the brighter peak of fluorescence emitted 
by the particles (Fig. 2 A). Hence, before starting the study, the multicolor particles were acquired 
several times using the same voltages determined for antibody staining of patients’ blood. A range 
of tolerance was built on the basis of the fluorochrome MFI associated to the marker to monitor. 
The range of tolerance is included within the mean ± 2x standard deviation of the measures (Fig. 
2 B). Every time a patient’s sample was run, the control multicolor particles were acquired in order 
to determine whether the MFI of the particles lay within the tolerance range.  
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Figure 1: Standardization of flow cytometer performance 
Panel A is representative of the fluorescence of multicolor particles in the APC channel. Panel B 
reports the MFI values of multicolor particles for independent experiments (black dot n=36), the 
tolerance range (red lines) and the 10th and 90th percentile of the measures (blue lines). The left and 
right plots of panel B describe the trend of MFI of APC (fluorochrome coupled to anti -HLA-DR 
antibody) and of PE (fluorochrome associated with anti -IL4Rantibody, respectively.  
Statistical analysis  
Wilcoxon Rank Sum test was used to compare the frequencies of myeloid and T cell subsets among 
healthy donors and melanoma patients at baseline, while Wilcoxon Signed Rank test was used to 
determine the level of significance among immunological parameters measured at W0 and W12.  
For identification of survival biomarkers, we defined OS as the time occurring between baseline 
and death or last contact with the patient.  
To identify two groups of patients with homogenous characteristics in terms of hematological 
parameters and myeloid and T cell subsets, the Cluster-K-means algorithm was used. Wilcoxon 
Rank Sum test was used to compare baseline and post-treatment levels of hematological or 
immunological parameters between the two clusters. Difference in OS between the two clusters 
was tested using Log-Rank test and the survival curves of the two groups were built according to 
Kaplan-Meier method.  
For univariate survival analysis, patients were divided in two groups according to the cohort-
median value of each hematological and immunological parameter at baseline or following 
ipilimumab treatment. Difference in survival between patients presenting values below or above 
the median for each parameter was tested using the Log-Rank test and the survival of each group 
was reported using Kaplan-Meier method.  
Correlations between hematological and immunological parameters were assessed at baseline 
and after ipilimumab treatment using Spearman Rank Order Correlation analysis.  
To identify potential correlations between survival and onset of toxicity, patients were divided 
according to the development of immune-related adverse events, and the difference between 
their OS was evaluated using the Log-Rank test. Survival curves were reported according to 
54 
 
Kaplan-Meier. A 2x2 contingency table was built on the basis of patients’ survival status and 
toxicity and the degree of correlation was tested using Fischer Exact Test.  
The association between toxicity and tumor-associated or immunological parameters (TIPs) was 
tested dividing the cohort in two groups according to the onset of irADR with severity above grade 
3. The level of significance among levels of TIPs was determined using Wilcoxon Rank Sum test or 
NonParametric Combination test202 to compare inter-group differences, while Wilcoxon Signed 
Rank test or NonParametric Combination test were used to compare intra-group variation of TIPs 
between W0 and W12.  
Results were considered statistically significant with P<0.05. All the statistical analysis were 
performed using SigmaPlot software v12.00 (Systat Software Inc.) and MiniTab software v17 
(Minitab Ltd.). 
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RESULTS 
HARMONIZATION OF IMMUNOPHENOTYPING OF HUMAN MYELOID-
DERIVED SUPPRESSOR CELLS 
At present, at least 7 myeloid cell subsets have been identified as MDSCs that encompass 
promyelocyte-like cells, monocytes and granulocytes. This heterogeneity, associated to the lack 
of a specific marker, hampered the identification of a simple and robust method of identification 
of these cells by flow cytometry. To overcome this obstacle, in collaboration with Dr. Walter 
(Immatics Biotechnologies, Tubingen) and Prof. Bronte (University of Verona) our group designed 
a proficiency panel to harmonize the phenotype of human MDSCs, under the umbrella of the 
Cancer Immunoguiding Program (CIP).  
Design of the MDSC-proficiency panel 
As preparative steps, we sent out two questionnaires to all the groups that published at least one 
paper on mouse and human MDSCs, exploring their interest in participating to the panel along 
with a number of questions referring to the procedures used for MDSCs identification. Participants 
were required to be experienced in multicolour flow cytometry. The panel design was based on a 
consensus of opinions from the preparatory process and it envisions a two steps approach. In the 
first step participants were asked to quantify 10 predefined phenotypes of putative MDSCs by 
multicolour flow-cytometry on centrally preselected cryopreserved PBMCs of three healthy 
donors (HBC-480, HBC-514, L29_3) using their own staining protocol, antibody clones, 
fluorochromes and gating strategy. We provided individual feedback for the results of each 
laboratory as compared to the entire group and we determined the inter- and intra-laboratory 
variance of results, indentifying a set of critical parameters influencing these indexes of variation. 
In the second step, laboratories will again perform quantification of 10 predefined MDSC 
phenotypes on blinded PBMC samples, but a number of mandatory harmonization guidelines 
deduced from the first step will be given. 
Guidelines for the first phase of MDSC proficiency panel 
The staining cocktail, proposed in the panel’s guidelines, contains 7 markers commonly used for 
MDSC recognition plus a DCM: HLA-DR, CD14, CD15, CD11b, CD33, Lineage cocktail (defined as 
CD3/14/19/56), CD124. This marker combination allows the identification of 10 myeloid subsets: 
MDSC1 CD14+/CD124+ 70, MDSC2 CD15+/CD124+ 70, MDSC3 Lin-/HLA-DR-/CD33+ 78, MDSC4 
CD14+/HLA-DRlow/- 72, MDSC5 CD15+/CD14-/CD11b+ 74, MDSC6 CD15+/FSClow/SSChigh 197, MDSC7 
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CD15-/CD14+/CD33high/HLA-DRlow 198, MDSC8 CD15+/CD33high, MDSC9 CD14-/CD15-/CD33high and 
MDSC10 Lin-/HLA-DRlow/CD11b+ 199(Fig.1). The list of the 10 putative MDSC subsets to be reported 
and the minimal composition of the staining cocktail are listed in Table 1.  
OBLIGATORY MYELOID PHENOTYPES 
TO BE DETERMINED 
MINIMAL COMPOSITION OF THE STAINING 
COCKTAIL 
MDSC1 = CD14+ CD124+ Anti-CD11b 
MDSC2 = CD15+ CD124+ Anti CD14 
MDSC3 = Lin- CD33+ HLA-DR- Anti-CD15 
MDSC4 = CD14+ HLA-DRlow Anti-CD33 
MDSC5 = CD15+ CD14- CD11b+ Anti-HLA-DR 
MDSC6 = CD15+ FSClow SSChigh Anti-CD124 (IL4R) 
MDSC7 = CD15- CD14+ CD33hi HLA-DRlow 
Lineage cocktail as defined here by anti-
CD14/CD19/CD3/CD56 
MDSC8 = CD15+ CD33hi Dead cell maker 
MDSC9 = CD14- CD15- CD33hi  
MDSC10 = Lin- HLA-DRlow CD11b+  
 
Table 1: Mandatory parameters for MDSC proficiency panel 
Table shows the 10 phenotypes to be determined (left column), and the minimal number of markers 
to be used (right column) for identification of the 10 putative MDSC subsets.  
Each participating laboratory was asked to perform the staining twice, in two separate 
experimental runs, and to report the number of total events, singlets, monocytes, lymphocytes 
and myeloid subsets in the presence or absence of the DCM. The reason of the repetition of the 
staining is to calculate intra-laboratory variance that gives an estimate of the reproducibility of 
results in each laboratory. Besides, as some MDSC subsets may be damaged by thawing 
procedures, we asked participants to perform analysis with or without the presence of a DCM, to 
prove whether some MDSC subsets were underestimated by the exclusion of dead cells. We also 
asked to use one 8-colors staining panel and/or three 4-colors panel staining, in order to include 
in the panel also the laboratories with flow cytometers equipped only for 4-colors analyses. 
Protocol of thawing and staining, fluorochrome and clone of antibodies, gating strategy and choice 
of negative controls were left free of choice. A detailed description of the mandatory instructions 
and the protocol used in our laboratory is reported in Material and Methods section. Twenty-
three laboratories from Europe and the United States of America participated to this first step of 
the proficiency panel, results were centrally collected and analysed in our laboratory and in the 
laboratory of Dr. Walter at Immatics Biotechnologies.  
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Figure 1: Exemplary gating strategy for the identification of 10 putative MDSCs subsets 
Exemplary gating strategy included in the panel’s guidelines  is reported. Preliminary doublets 
exclusion (FSC-H vs FSC-A)(A) followed, when required, by dead cell exclusion (B) was suggested 
before proceeding with the identification of 10 myeloid subsets indicated in the figure with letters 
from C to N.  
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Determination of intra- and inter-laboratory variance 
To ascertain the variance among results, we calculated the % coefficient of variation (standard 
deviation/mean x 100). Intra-laboratory variance was defined as the variance of results between 
the first and second experimental runs in each laboratory, while inter-laboratory variance was 
defined as the variance occurring in results obtained by the 23 different laboratories in the two 
experimental runs.  
Intra-laboratory variance ranged from 24 to 52% (Fig. 2 A), and was almost uniform among the 
different subsets, but inter-laboratory variance was higher, ranging from 64 to 310%, Fig. 2 C, and 
with high variation in the different subsets. In fact, variance was higher when assessing 
granulocytic subsets (MDSC2-5-6-8, range 200-310%), intermediate for immature MDSCs (MDSC3-
10, range 100-170%), and presented the lower coefficient of variation with monocytic MDSCs 
(MDSC 4-7, range 64-75%). A different matter is related to MDSC1 cell subset estimation, that 
shows a very high variance (range 180-210%), but this was likely due to other parameters used for 
CD124+ cell identification (see later). We also observed that the use of DCM significantly increased 
intra-laboratory variance (P<0.001 on overall MDSC populations according to Wilcoxon Signed 
Rank test) (Fig. 2A), while inter-laboratory variance does not change significantly (Fig. 2C). We 
reported individual results for three MDSC subsets, representative of the three main classes of 
MDSCs, as an example of the great variation in the quantification of these cells (Fig. 2 B).  
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Figure 2: Intra-laboratory and inter-laboratories variance  
Immunophenotyping of 10 putative MDSCs subsets was performed on PBMC of 3 healthy donors 
(HBC-480, HBC-514, L29_3) in two independent experimental runs. Intra-laboratory and inter-
laboratory variance are shown in panel A) and C), respectively. Black bars showed average %CV from 
analyses performed without exclusion of dead cells, while white bars refers to analyses considering 
only live cells. (P<0.001 on overall MDSC populations according to Wilcoxon Signed Rank test for 
difference in intra-laboratory variance). n=18 evaluable labs reporting data for the 8 -color panel. 
Laboratories that did not report all requested data were not considered evaluable,  while laboratories 
performing 4-color panels were excluded in order to perform analysis on a more homogeneous 
cohort. Panel B) showed an example of the frequencies of monocytic (MDSC4 – upper panel), 
granulocytic (MDSC5 – central panel) and immature (MDSC10 – lower panel) MDSCs, normalized on 
the count of lymphocytes+monocytes, reported by each laboratory performing either one 8 -color 
panel or three 4-color panels; the two paired-histograms refer to the two independent experimental 
runs performed by each laboratory (black bars = first run, grey bars = second run). Missing values “m”.  
In order to reduce variance, we normalized data by diving the number of each MDSC subset on 
the total count of lymphocytes plus monocytes and by reporting the value to 100. This 
normalization reduced the variance between laboratories for 7 out of 10 subsets (Fig. 3 A) but 
heterogeneity of the results was still very high even after normalization, and thus we set out to 
identify potential parameters responsible for this high spread. As shown in Figure 3 B, the use of 
DCM affects the quantification of the myeloid subsets, as it brings about a significant reduction of 
granulocytic subsets and, to a minor extent, also of immature subsets. On the contrary, the 
quantification of monocytic MDSCs (MDSC 4-7) is unaffected by the use of DCM. A possible 
explanation of these results lies in the fragile nature of granulocytes that are more prone to death 
during the thawing procedure, as compared to monocytic cells.  
Identification of critical parameters influencing the variance of results 
By analysing a number of parameters potentially affecting the variance, we found that an 
important source of variation was the gating strategy adopted by the groups to identify MDSCs 
subsets. To dissect the influence of the gating strategy on inter-laboratory variance, we compared 
the variance of 9/18 groups adherent to a homogeneous gating strategy, which corresponds to 
the strategy exemplified in the panel’s guidelines, to those who were using a number of different 
gating strategies, distinct from that proposed in the guideline (9/18). Indeed, we detected a 
significant difference in the overall coefficient of variation when we compared these two groups 
(Fig. 3 C, P=0.0012 on overall MDSC populations according to Wilcoxon Signed Rank test). To 
minimise the interference on variance analysis given by other covariates, we considered for this 
analysis 18/23 laboratories that identify the 10 putative MDSC subsets using an 8-color panel and 
analysing data without DCM.  
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Figure 3: Candidate parameters affecting inter-laboratory variance 
Immunophenotyping of 10 putative MDSCs subsets was performed by staining the PBMCs of 3 healthy 
donors (HBC-480, HBC-514, L29_3) in two independent experimental runs.  Panel A shows average 
%CV (n=14 evaluable labs reporting data for the 8-color panel) of the frequencies of the ten MDSC 
subsets normalized according to different strategies. Results are reported without normalization 
(Black bars) and normalized on the number of singlets (yellow bars), lymphocytes (blue bars) and 
lymphocytes + monocytes (red bars) for each MDSC subset. Panel B shows the average normalized 
frequencies of MDSC subsets (n=18 evaluable labs reporting data for the 8 -color panel), normalized 
on lymphocytes + monocytes identified either excluding (white bar) or not (black bars) the dead cells.  
C) Average %CV (n=18 evaluable labs reporting data for the 8-color panel) of the frequencies of MDSC 
subsets identified either using an homogenous gating strategy (white bar) o r not (black bars). 
Differences between data have been tested using Wilcoxon Signed Rank test and labelled as *** when 
P<0.001 or as **** when P<0.0001. 
As previously stated, the inter-laboratory variance for MDSC subsets identified by CD124 marker 
(MDSC1 and MDSC2) was high, ranging from 178 to 210% for MDSC1 and from 251 to 310% for 
MDSC2. To identify the possible sources of high variance for these subsets, we harmonized CD124-
independent parameters which may otherwise influence the analysis: to this end, we considered 
only 16/23 laboratories that used an 8-color panel, analysed data without dead cell marker and 
chose one of the two most used anti-CD124 clones for identification of CD124+ cells; in addition, 
we based our analysis on MDSC1 because the low frequencies of MDSC2 would lead to high %CV 
even in the presence of low relative difference between measurements. We identified two 
possible parameters responsible for the high variance of MDSC1: the gating strategy and the anti-
CD124 clone. Indeed, CD124 is a marker characterized by a dim intensity and a unimodal 
distribution of the signal, and identification of positive cells brings about a certain degree of 
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complexity. Indeed, participants identified CD124+ cells following two distinct gating strategy: 
9/16 groups set the gate for CD124+ cells only considering cells with high intensity of this marker 
(Fig. 4 Ai), while 7/16 included also cells with a dim expression (Fig. 4 Aii). This decision determined 
a very high difference in MDSC1 quantification, given equal clones used for staining (Fig. 4 B), and 
thus the overall variance for MDSC1 raised, but the %CV was similarly reduced when we separated 
the results on the base of the gating strategy (Fig. 4 C). The second main source of variation 
between data lies on the choice of anti-CD124 clone. 20/23 laboratories used two clones for 
CD124 identification (n=13 clone hIL4R-M57, n=7 clone 25463) and we recorded a discrepancy 
between their staining potential: on equal gating strategy, clone 25463 identified higher 
frequencies of MDSC1 than clone hIL4R-M57 (Fig. 4 D).  
 
Figure 4: Parameters affecting inter-laboratory variance for MDSC1 
Quantification of MDSC1 was included in the immunophenotyping of the 10 putative MDSCs subsets 
performed on PBMC of 3 healthy donors (HBC-480, HBC-514, L29_3) in two independent experimental 
runs. Figure shows results relative only to MDSC1. In this analysis 16 laboratories out of 23 were 
included as they performed an 8-color panel staining that included either anti-CD124 clones hIL4R-
M57 or 25463, and data were analysed without exclusion of dead cells. A) Two different exemplary 
gating strategies for determination of CD124+ cells. CD124+ cells determined as those expressing a 
high fluorescence intensity for this marker (i) or as those dimly fluorescent (ii). Panel B shows the 
average normalized frequencies of MDSC 1 normalized on lymphocytes + monocytes identified either  
including cells with high (black bars) or high + dim (grey bars) fluorescence . Comparison between 
different gating strategies was performed on equal clones (either hIL4R -M57 or 25463) as indicated 
on the top of the plot. C) Average %CV of the frequencies of MDSC1 determined as those expressing 
a high fluorescence intensity for CD124 (gated on high) or as those dimly fluorescent (gated on dim) 
or any gating strategy (all). Panel D depicts the average frequencies of MDSC 1 normalized on 
lymphocytes + monocytes identified either using anti-CD124 clone hIL4R-M57 (black bars) or 25463 
(grey bars). Comparison between different staining potential was performed on equal gating strategy 
as indicated on the top of the plot. 
Immature MDSCs are defined as myeloid cells with low or negative expression of HLA-DR and 
negative for the staining of Lineage cocktail. In the panel’s guidelines we proposed to use a Lineage 
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cocktail properly excluding T, B and NK cells plus monocytes. However, only 12/23 laboratories 
used the proposed Lineage cocktail. 6/23 used a cocktail including markers only for T, B 
lymphocytes and NK cells while 5/23 used a Lineage cocktail with a richer composition including 
markers for T, B lymphocytes and NK cells, monocytes and granulocytes. This discrepancy probably 
increased the variance of the results (range 100-170% Fig. 2 C) and the addition of a granulocytic 
marker in the Lineage cocktail led to identification of more defined, albeit lower, percentage of 
immature subsets (data not shown).  
Future perspectives for the second experimental step  
Results from the first phase of the proficiency panel demonstrate that participants identified the 
10 putative MDSC subsets with good intra-laboratory reproducibility but with a very high inter-
laboratory variance, thus supporting the need of an effort for the harmonization of human MDSC 
determination. Such large variance may be partially corrected by normalizing the results on an 
internal control (number of lymphocytes plus monocytes) and using a homogenous gating strategy 
for MDSC identification. To this end, we are currently setting up an in-silico panel to clearly assess 
the influence of the gating strategy on the spread of the results and to identify a robust gating 
strategy that will be used in the second step of the proficiency panel. Other aspects that require 
attention are the use of DCM and the identification of CD124+ cells. Indeed, as the presence of 
DCM significantly impacted on intra-laboratory variance and on quantification of granulocytic 
subsets, we will discuss with the participants whether it is recommendable to include the DCM in 
the staining. Other issues open for discussion are the harmonization of CD124 staining, and the 
composition of the Lineage cocktail. 
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IMMUNOMONITORING OF MELANOMA PATIENTS TREATED WITH 
IPILIMUMAB  
Clinical characteristics of the cohorts 
We enrolled 37 patients affected by metastatic melanoma and selected to receive ipilimumab. 
The mean age of the cohort was 63 years (range 33-83) and it was composed of 25 males (68%) 
and 12 females (32%). In parallel, we enrolled also 21 healthy donors matched for age and gender: 
the mean age of this cohort was 58 years (range 37-87) and it was composed of 14 males (67%) 
and 7 females (33%). Clinical characteristics of melanoma patients and healthy controls are 
detailed in Table 2.  
At baseline, all melanoma patients were affected by metastatic disease (stage IV) and the majority 
of them (n=25, 67%) presented with IV M1c stage, which is characterized by the presence of 
visceral metastasis and/or elevated LDH levels, eight patients (22%) had stage IV M1b with lung 
metastasis and normal LDH levels, and only a minority of patients had distant metastasis restricted 
in the skin and normal LDH levels (stage IV M1a, n=4, 11%). Albeit the high prevalence of late stage 
patients, the Eastern Cooperative Oncology Performance Status (ECOG PS) was good for most of 
the patients (n=27, 73% ECOG PS ≤ 1).  
Most of the patients were previously genotyped for B-RAF and N-RAS mutations (n=35, 99,3%). 
59% of the patients did not carry any mutations in these genes while 31% presented B-RAF 
mutations and were pre-treated with B-RAF inhibitors. Only one patient have a mutation on N-
RAS.  
Baseline levels of circulating tumor cells (CTC) was also available from 11 patients (36%) who 
presented elevated or stable CTC post-treatment. However, this low number of patients reduced 
the power of any statistical association with immune parameters and therefore we did not include 
this parameter in our statistical analysis. 
Ipilimumab treatment was successfully completed for 28 patients (75%), while one fourth of the 
patients discontinued the treatment because of toxicity or death (n=9, 25%). The median time to 
progression was 12 weeks and partial response was achieved by 19% of the patients (n=7), 11% 
had a stable disease (n=4), and 70% of the patients did not control the disease (n=25). Complete 
responses were not achieved in this group of patients. OS was evaluated: one-year survival rate 
was 43% while 62% of the patients were still alive when survival was measured at the common 
minimum time of follow-up, that is 29 weeks for this study (W29).  
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 PATIENTS HEALTHY DONORS 
N 37 21 
Age (mean, range) 63 (33-83) 58 ( 37-87) 
Gender M/F (n, %) 25/12 (68/32%) 14/7 (67/33%) 
  n %  
ECOG PS 
≤ 1 27 73  
2 10 27  
Stage 
M1a 4 11  
M1b 8 22  
M1c 25 67  
Mutations (n=32) 
WT 19 59  
B-RAF 10 31  
N-RAS 1 0,3  
ND 2 0,7  
CTC (n=11) W0 4 36  
Variation of CTC (W12-W0) 
up 4 36  
down 2 18  
stable 5 46  
Ipilimumab therapy 
completed 28 75  
not completed 9 25  
Response W12 
Median TTP 12 weeks   
CR 0 0  
PR 7 19  
SD 4 11  
PD 25 70  
Survival 
Median OS 32 weeks   
1-year OS n=28 11 43%  
Alive W29 23 62  
Deceased W29 14 38  
 
Table 2: Baseline characteristics of melanoma patients and healthy donors  
Response was assessed 12 weeks upon enrollment according to immune-related response criteria and 
classified as follows: complete response (CR), partial response (PR), stable disease (SD), progressive 
disease (PD). Eastern Cooperative Oncology Performance Status (ECOG PS), Circulating Tumor Cells 
(CTC), week 0 (W0), week 12 (W12). 
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Evaluation of the immune profile of melanoma patients at baseline  
The first step of this study compared the immune profile of melanoma patients with healthy 
donors to evaluate the modifications induced by melanoma in the immune system of these 
patients. To this end, we investigated different populations of circulating myeloid cells, T cells and 
serum proteins named haematological parameters herein. 
Among the myeloid cells analysed, we considered four subsets of MDSCs, eosinophils and putative 
dendritic cells (DCs). Given the high heterogeneity of phenotypes attributed to MDSCs, we chose 
to monitor the presence of two monocytic, one immature ad one granulocytic subsets because 
they are the most common MDSC subsets found in the whole blood of cancer patients57. Since we 
phenotyped MDSCs on whole blood, it was not possible to monitor also the levels of low-density 
polimorphonuclear cells that often co-purify with PBMCs in cancer patients and constitute a 
subsets of granulocytic MDSCs75. The phenotypes of MDSCs subsets assayed in this study are 
reported in Figure 5: MDSC 1 (CD14+/IL4R+, panel B), MDSC 2 (CD15+/IL4R+, panel D), MDSC 3 
(CD15-/Lin-/HLA-DR-/CD33+/CD11b+, panel E), MDSC 4 (CD14+/ HLA-DR low/-, panel C). 
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Figure 5: Identification of four MDSC subsets in whole blood by multicolour flow 
cytometry 
A) Gating strategy to identify MDSCs consists in the definition of a morphological gate, set on FSC vs 
SSC parameters, followed by exclusion of doublets and dead cells and further definition of MDSC 
subsets as illustrated in panels B-E. B) and C) illustrate the gating strategy to identify monocytic MDSC: 
MDSC1 (CD14+/IL4R+, panel B) and MDSC4 (CD14+/ HLA-DR low/-, panel C); panel D exemplified the 
gating strategy for granulocytic MDSC2 (CD15+/IL4R+) while panel E shows the gating strategy for 
immature MDSC3 (CD15-/Lin-/HLA-DR-/CD33+/CD11b+). The MDSC subsets reported belong to 
different patients indicated in the figure with the acronym PDO plus the serial number of the sample. 
FMO controls were used for HLA-DR and IL4Relectronic gating.  
Eosinophils were defined using the pan-granulocytes marker CD15 and considering their peculiar 
intense autofluorescence at 520nm, when excited with the 405nm violet laser. The use of 
autofluorescence to identify eosinophils was previously reported by other authors203,204 and it is 
primary due to flavins contained in their granules. The gating strategy to identify eosinophils is 
depicted in Figure 6.  
 
 
Figure 6: Identification of eosinophils in whole blood by multicolour flow cytometry 
Peripheral blood leukocytes were analysed using a morphological gate set on FSC vs SSC parameters. 
After exclusion of doubles and dead cells, the eosinophils’ population was defined on the basis of 
CD15 expression and of high autofluorescence in the V500 channel. To confirm that gated cells belong 
to the myeloid lineage, the pan-myeloid markers CD33 and CD11b were also used. As shown in the 
overlay representation, eosinophils have high SSC and a characteristic autofluorescence in the V500 
channel. 
Finally we identified a subset of myeloid cells which did not express markers of mature 
lymphocytes, granulocytes and monocytes and expressed high levels of HLA-DR (CD15-/Lin-/HLA-
DR+/CD33dim). This phenotype is compatible with the phenotypic definition of DCs. The gating 
strategy for this putative DCs subset is depicted in Figure 7.  
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Figure 7: Identification of putative dendritic cells in whole blood by multicolour flow 
cytometry 
Putative DCs were identified among blood leukocytes by using a morphological gate set on FSC vs SSC 
parameters. After exclusion of doubles, dead cells and CD15+ granulocytes, mature monocytes and 
lymphocytes were excluded by a progressive gating on Lineage - cells and putative DCs  were identified 
on the basis of the high expression of HLA-DR and of a dim expression of CD33. In the overlay 
representation, these cells are characterized by peculiar SSC properties, i.e. lower than monocytes 
but higher than lymphocytes.  
Melanoma patients showed a significant expansion of MDSC-1, -2 and -4 subsets in the blood, and 
had reduced frequencies of eosinophils compared to healthy donors, while putative DCs and 
MDSC 3 levels did not differ significantly from the control group of healthy donors, matched by 
age and gender (Fig. 8 C-F). Both subsets of MDSCs expressing IL4Rhad a significant expansion 
(MDSC1 P<0.001, Fig. 8 A, and MDSC2 P=0.009, Fig. 8 B), along with MDSC4 (P=0.004, Fig. 8 D). In 
addition, melanoma patients presented significantly lower levels of circulating eosinophils 
compared to healthy donors (P= 0.001, Fig 8 E). 
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Figure 8: Baseline levels of myeloid cells in stage IV melanoma patients and healthy 
donors. 
Baseline levels of myeloid subsets in melanoma patients (MEL, n=27 to 33 depending on t he myeloid 
subset considered) and age- and gender-matched healthy donors (HD n=21) are shown. Each box plot 
show first and third quartiles and median values of the myeloid subset indicated at the top of the 
plot. Outlier are plotted as individual points. Wilcoxon Rank Sum test was used to compare the 
frequencies of myeloid subsets between the two groups (** P<0.01, *** P<0.001). Values were 
considered statistically significant for P<0.05. 
Frequencies of T cell subsets were assessed on whole blood by restricting the analysis among 
PBMCs (Fig. 10 A), and absolute counts of these cells were obtained using Trucount tubes (Fig. 10 
C). We considered both total CD3+ T cells (Fig. 9 B) and their major sub-population: CD3+/CD4+ and 
CD3+/CD8+ T cells (Fig. 9 C-D). In addition, we decided to monitor PD-1 expression on both T cell 
subsets. The expression of PD-1 was evaluated as frequency and as absolute numbers of 
CD3+/CD4+/PD-1+ and CD3+/CD8+/PD-1+ cells; we also quantified PD-1 expression within each T cell 
subsets (Fig. 9 E-F). Gating strategy is reported in Figure 9. Cumulative results are depicted in 
Figure 10.  
At baseline melanoma patients did not show an altered frequency of total CD3+ T cells and T cell 
subsets compared to healthy donors (Fig. 10 A), but the absolute count of total T lymphocytes was 
significantly reduced (Fig. 10 C, P<0.001). This was primary due to a reduction in the number of 
CD3+/CD4+ cells while the number of CD3+/CD8+ cells was unaffected (Fig. 10 C, P<0.001 for 
CD3+/CD4+ cells). Of note, we observed a significant up-regulation of PD-1 expression on CD4+ T 
cells compared to healthy donors (Fig. 10 B) and indeed, the count of PD-1+ cells was elevated in 
both lineages of T cells compared to controls (Fig 10 C P=0.007 for CD3+/CD4+/PD-1+ cells and 
P<0.001 for CD3+/CD8+/PD-1+ cells).  
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Figure 9: T cell subsets identification in whole blood by flow cytometry 
PBMCs were included in the analysis using a morphological gate set on FSC vs SSC parameters (A). 
After exclusion of doublets, CD3+ T cells were considered (panel B). CD4+ and CD8+ T cells were 
identified as reported in panels C and D, respectively. PD-1+ cells were quantified within each T cell 
subset (panels E-F), setting the gate on FMO control.  
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Figure 10: Baseline frequencies and absolute numbers of T cell subsets in melanoma 
patients and healthy donors 
(A) Baseline frequencies of T cell subsets in melanoma patients (PT, n=37) and age- and gender-
matched healthy donors (HD n=21). (B) frequencies of PD-1+ cells within the CD4+ or CD8+ subsets of 
T lymphocytes. (C) absolute count of T cell subsets in a group of patients (n=22) and healthy donors 
(n=10). Each box plot shows first and third quartiles and median values of the T cell subset indicated 
at the top of the plot. Outlier are plotted as individual points. Wilcoxon Rank Sum test was used to 
compare the frequencies of T cell subsets between melanoma patients and healthy donors (* P<0.05, 
** P<0.01, *** P<0.001). Values were considered statistically significant for P<0.05. 
We also assessed the levels of serum factors of melanoma patients that are associated either with 
the immunological status of patients or with tumor-burden. In detail, we considered circulating 
levels of: i) C-reactive protein (CRP) and interleukin-6 (IL-6), which are proteins associated with 
inflammation and MDSCs expansion32,107,108, and ii) vascular endothelial growth factor (VEGF), 
lactate dehydrogenase (LDH) and S100B, which are related to angiogenesis, tumor burden and 
contribute to staging of metastatic melanoma (LDH)57,179. As shown in Table 3, about half of the 
patients presented consistent alteration of CRP and S100B levels at baseline, while a lower 
proportions of patients had altered VEGF, IL6 and LDH levels compared to the upper limit of 
normal (ULN).  
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Baseline Post-treatment 
%Below 
ULN 
%Above 
ULN 
%Below 
ULN 
%Above 
ULN 
C-reactive protein (CRP) 50 50 53 47 
Interleukin 6 (IL6) 79 21 65 35 
Vascular endothelial growth factor 
(VEGF) 
70 30 65 35 
S100B 47 53 29 71 
Lactate dehydrogenase (LDH) 65 35 40 60 
 
Table 3: Haematological parameters in melanoma patients. 
Percentage of patients with values of serum factors below or above the ULN at baseline and post -
treatment. 
In conclusion, melanoma patients significantly expanded three subsets of MDSCs (MDSC 1-2-4) 
and had lower frequencies of eosinophils compared to healthy donors. Besides, patients 
underwent significant alterations in the T cell compartment showing lower numbers of T 
lymphocytes, especially CD4+ T cells, and an up-regulation of PD-1 on CD4+ T cells. Finally, patients 
presented altered levels of serum proteins associated with inflammation and tumor burden such 
as CRP and S100B.  
Immune profile of melanoma patients during ipilimumab treatment 
Since ipilimumab exerts its major functions through modulation of the T cell response, we 
investigated whether the administration of the drug was able to induce also a modification in the 
immune profile of patients. To this end, we compared the parameters evaluated at baseline (W0) 
also after 12 weeks (W12), when patients underwent to their first clinical evaluation of response 
via CAT. 
In the myeloid compartment we observed a significant reduction of immature MDSC3 in post-
treatment samples compared to baseline (Fig. 11 C, P=0.024) and a significant expansion in the 
putative DC subset Lin-/HLA-DR+/CD33dim (Fig. 11 F, P=0.017). On the other hand, MDSC 1-2-4 and 
eosinophils, which were significantly altered at baseline compared with healthy donors, did not 
change significantly upon treatment with ipilimumab (Fig. 11 A-B-D-E). 
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Figure 11: Evaluation of myeloid subsets during ipilimumab treatment  
Levels of myeloid subsets monitored in melanoma patients at W0 (n=20 to 24 depending on the 
myeloid subset considered) and at W12 (n=20 to 24 depending on the myeloid subset considered). 
Each box plot shows first and third quartiles and median values of the myeloid subset indicated at the 
top of the plot. Outliers are plotted as individual points. Wilcoxon Signed Rank test was used to 
compare the frequencies of myeloid subsets in melanoma patients at different time-points (*P<0.05). 
Values were considered statistically significant for P<0.05. 
Ipilimumab treatment did not change total percentage of CD3+ T cells, nor their absolute number 
(Fig. 12 A-B). On the contrary, following treatment PD-1 expression was significantly up-regulated 
on both CD4+ and CD8+ T cell subsets (Fig. 12 A, P=0.003 for CD3+/CD4+/PD-1+ cells and P=0.016 for 
CD3+/CD8+/PD-1+ cells). This effect was not due to an expansion of CD4+ or CD8+ T cells, whose 
frequencies and absolute numbers remained stable (Fig. 12 A-C), and it is even more significant 
when considering the percentages of PD-1+ cells within the CD4+ or CD8+ gate (Fig.12 B, P<0.001 
within CD4+ T cells and P<0.001 in CD8+ T cells).  
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Figure 12: Changes of T cell subsets following ipilimumab treatment  
Frequencies and absolute numbers of T cell subsets monitored in melanoma patients at W0  (n=29 for 
percentages and n=16 for absolute count) and at W12 (n=29 for percentages and n=16 for absolute 
count). Panel A shows the frequencies of T cell subsets referred to PBMC. Panel B shows the frequency 
of PD-1+ cells referred to CD4+ or CD8+ subsets while the absolute count of T cell subsets are reported 
in panel C. Each box plot shows first and third quartiles and median values of the T cell subset 
indicated at the top of the plot. Outlier are plotted as individual points. Wilcoxon Signed Rank test 
was used to compare the frequencies of T cell subsets in melanoma patients at different time -points 
(* P<0.05, ** P<0.01, *** P<0.001). Values were considered statistically significant for P<0.05. 
We monitored also the potential effect of ipilimumab on hematological parameters, but the levels 
of these serum proteins remained stable upon treatment with the exception of a significant 
increase in circulating S100B (Fig 13, P=0.036). 
74 
 
 
 
Figure 13: Evaluation of hematological parameter during ipilimumab treatment  
Serum levels of proteins at W0 (n=37 to 34 depending on the considered parameter) and at W12 (n= 
31 to 29 depending on the considered parameter). Each box plot shows first and third quartiles an d 
median values of the hematological parameter indicated at the top of the plot. Outlier are plotted as 
individual points. Wilcoxon Signed Rank test was used to compare levels of hematological parameter 
in melanoma patients at different time-points (* P<0.05). Values were considered statistically 
significant for P<0.05. 
Overall, ipilimumab treatment did not alter significantly the immune profile of the patients in this 
study with the exception of a significant up-regulation of PD-1 on both CD4+ and CD8+ T cell subsets 
and an increase in serum levels of S100B.  
Identification of early predictors of toxicity 
It has been demonstrated that ipilimumab treatment is associated with a toxicity profile mainly 
due to irADR consequent to an impairment of tolerance towards self-antigens173. We investigated 
whether toxicity was correlated with tumor-associated and immunological parameters (TIPs), like 
myeloid subsets, T cell subsets and hematological parameters. To this end, we grouped the 
patients on the basis of development or absence of grade 3 immune-related adverse reactions 
(ADR+ and ADR-) and we compared W0, W12 frequencies and absolute (W12/W0) or relative 
(W12 minus W0) variations of TIPs among the groups.  
We observed that patients with lower incidence of irADR expressed higher levels of PD-1 on CD4+ 
T (Fig. 14 B P=0.011), however, the presence of irADR was mainly reflected by post-treatment 
measures of TIPs. In fact, upon treatment, we observed a further up-regulation of PD-1 expression 
on CD4+ and CD8+ T cells of ADR- patients compared to baseline (Fig. 14 B-D P<0.001 and Fig. 14 
C-E P=0.003). Besides, after ipilimumab treatment patients without grade 3 toxicity were 
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characterised by a significant expansion of CD3+ T cells (Fig. 14 A P=0.006) and by a significant 
decrease of immature MDSC3 (Fig. 14 F P=0.04). On the contrary, ADR+ patients failed to up-
regulate PD-1 expression on T cells, that, in turns, were significantly reduced compared to ADR- 
patients (Fig. 14 A P=0.05) at W12. The presence of toxicity was associated also to a trend toward 
lower frequency of eosinophils (Fig. 14 H) and wider variance in MDSC4 (Fig. 14 G) at W12.  
 
 
Figure 14: Early predictors of toxicity 
Box plots report median, first and third quartiles of TIPs measured at W0 and W12 in patients without 
ADR- or with ADR+. Outlier are plotted as individual points. Significance of intra-group variations 
between W0 and W12 values were assed using Wilcoxon Signed Rank Test while Wilcoxon Rank Sum 
Test was used to compare inter-group variations (* P<0.05, ** P<0.01, *** P<0.001)). Values were 
considered statistically significant for P<0.05. 
Since high grade toxicity is a sign of hyper-activation of the immune system, some authors 
correlated the development of irADR to efficacy of ipiliumab treatment205,206. However, we did not 
find evidence of association between toxicity and OS (P=1,00 using Fischer Exact Test, P=0.950 
using Log-Rank test Fig. 15), in line with a recent report179. 
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Figure 15: Correlation between immune-mediated toxicity and clinical efficacy of 
ipilimumab 
A) Pie plot represents proportions of ADR+ and ADR- patients according to their survival status at W29 
(Dec= deceased). B) Kaplan-Meier estimates of survival for ADR+ and ADR- patients. Values were 
considered statistically significant for P<0.05.  
In conclusion, our results indicate that the development of toxicity was not predictive for longer 
OS in response to ipilimumab, but it is associated with reduced CD3+ T cells, increased variance in 
MDSC4 and lower frequencies of eosinophils at W12. Interestingly, we observed an also an 
association between lower toxicity and reduced baseline expression of PD-1 on CD4+ T cells. 
Besides, ADR- patients expanded T lymphocytes, and in particular PD-1 expressing T cells, upon 
treatment.  
Identification of biomarkers associated with overall survival  
Ipilimumab treatment has demonstrated survival advantages in pre-treated metastatic melanoma 
patients, when compared to gp-100 peptide vaccine41, but validated predictors of OS are still 
missing. We exploited our dataset of TIPs, to identify potential biomarkers of OS. We defined OS 
as the time occurring between baseline and death or last contact with the patient and we planned 
three different statistical strategies for survival analysis. We first performed an exploratory 
unsupervised multivariate analysis, dividing the cohort of patients in two clusters, characterized 
by homogeneous levels of TIPs, and subsequently testing for a difference in OS between the two 
clusters. The second step was to divide the patients on the basis of their survival status (alive vs 
deceased) at a homogeneous time-point and test whether there was a difference in the levels of 
TIPs in the group of alive and deceased patients. In the third step, results of this analysis were 
further confirmed using univariate survival analysis in which patients were stratified on the basis 
of the cohort-median value of the TIP under investigation and testing whether a significant 
difference in OS was present between the two groups.  
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Cluster analysis of tumor-associated and immunological parameters 
In this analysis we considered the frequencies and absolute variations of TIPs at W0 and at W12. 
Parameters were analysed in three homogeneous groups: hematological values (CRP, IL6, VEGF, 
S100B), myeloid cells (MDSC1-2-3-4, eosinophils, putative DCs), and T lymphocytes 
(L1=%CD3+/CD4+, L2=%CD3+/CD8+, L3=%CD3+/CD4+/PD-1+, L4=%CD3+/CD8+/PD-1+, L5=%PD-1+ in 
CD3+/CD4+, L6=%PD-1+ in CD3+/CD8+, L7=%CD4/%CD8, L8=%CD3+). In each group, two clusters 
with homogeneous baseline values were identified using Cluster K means algorithm and 
difference in OS between clusters was tested using the Log-Rank test. 
Results of this analysis do not demonstrate significant correlations between clusters of baseline 
TIPs and OS, a part from a trend towards better prognosis in patients with lower baseline levels of 
hematological parameters IL-6, CRP, VEGF and S100B and higher levels of T lymphocytes (Fig. 16). 
 
Figure 16: Kaplan-Meier estimates for overall survival 
Survival of cluster 1 and 2 using Kaplan-Meier curves in panel A,B,C. Median baseline levels of the 
indicated TIPs are shown in panels D,E,F. Difference between baseline values of TIPs in the two 
clusters was tested using Wilcoxon Rank Sum test. Values were considered statistically significant for 
P<0.05.  
 On the contrary, when we analysed post-treatment levels, or the variation of TIPs following 
treatment, we observed significant associations with OS. Indeed, higher absolute variations in 
hematological parameters, and in particular significantly higher absolute variations of VEGF (Fig. 
17 C, P=0.013), conveyed a survival advantage (Fig. 17 A, P<0.001). 
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Analogously, lower frequency of putative DCs and MDSC subsets, (significant for MDSC 1-2-4), 
coupled to an increased presence of eosinophils in the blood of patients following ipilimumab 
treatment described an immune profile of patients with better prognosis (Fig. 17 B). In particular, 
the main difference between the two clusters consisted in a significant reduction of the MDSC 
subsets expanded at baseline (MDSC1-2-4) in patients with longer OS (Fig. 17 E, P<0.001 for 
MDSC1, P=0.004 for MDSC2, P=0.03 for MDSC4). On the contrary, greater relative variations of T 
cell subsets upon treatment were associated with prolonged OS (Fig. 17 C). Indeed, the group of 
patients with better prognosis presented significantly higher CD3+, CD3+/CD4+, CD3+/CD8+ T cells 
and a major up-regulation of CD4+ T lymphocytes expressing PD-1 (Fig. 17 F, P<0.001 for CD3+, 
P<0.001 for CD3+/CD4+, P=0.019 for CD3+/CD8+ , P<0.001 for CD3+/CD4+/PD-1+ cells).  
 
Figure 17: Kaplan-Meier estimates for overall survival 
Absolute variations of hematological parameters (A-D), post-treatment levels for myeloid subsets (B-
E) and relative variations of T lymphocytes (C-F) were considered for cluster analysis. Kaplan-Meier 
curves are referred to OS of the two clusters shown in panels A-B-C, while panels D-E-F reported 
median variations of the indicated TIPs. Difference between TIPs in the two clusters was tested using 
Wilcoxon Rank Sum test. Values were considered statistically significant for P<0.05. 
Univariate survival analysis 
To identify potential TIPs representing early predictors of OS, we performed a univariate analysis. 
We thus divided the patients in two groups, alive or deceased at W29; we considered this time 
interval as homogenous because it represents the minimum period of follow-up of the cohort 
following ipilimumab treatment. For each group, we compared W0, W12, the relative or absolute 
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variations of TIPs in the two groups. When a trend toward association between a parameter and 
the survival status was identified, we confirmed the result by testing the difference between OS 
of patients characterized by values below or above the median of the group for that parameter.  
This strategy revealed some interesting associations between TIPs and OS and the description of 
results will be divided in three parts accounting for the three main classes of TIPs: haematological 
parameters, T cell subsets and myeloid subsets.  
Haematological parameters 
When we considered parameters involved in inflammatory conditions like CRP and IL-6, we found 
that patients deceased at W29 presented significantly higher levels of CRP post-treatment (Fig. 18 
A, P=0.023). Albeit not statistically significant, the same tendency was present also considering 
baseline CRP values (Fig. 18 A, P=0.058). Indeed, survival analysis confirmed the tendency towards 
a worse prognosis for patients presenting with CRP levels above the median of the cohort at 
baseline (Fig. 18 B). In the same way, we detected a significant association between both W0 and 
W12 levels of IL-6 and prognosis (Fig. 18 D, P= 0.015 and P= 0.011, respectively). The survival 
analysis confirmed that lower levels of IL-6 in the serum are strongly predictive of longer OS in 
patients treated with ipilimumab (Fig. 18 E-F, P=0.006 baseline, P=0.041 post-treatment).  
 
Figure 18: Survival estimates according to levels of CRP and IL-6 
W0 and W12 values of CRP and IL-6 are reported in panels A and D, dividing the cohort of patients in 
two groups on the basis of the survival status at W29. Box plot report median, first and third quartiles. 
Outlier are plotted as individual points. Wilcoxon Rank Sum Test was used to compare inter-group 
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variations (* P<0.05). Kaplan-Meier curves referred to survival analysis are reported in panels B-C-E-
F. Panels A-B-C show association between OS and CRP levels while panels C-D-E depict results about 
IL-6. Values were considered statistically significant for P<0.05.  
We then correlated OS with B-RAF mutations, LDH, S100B and VEGF. Patients were divided in two 
groups on the basis of: i) presence (B-RAF mut) or absence (WT) of mutations in V600 codon of 
the B-RAF gene; ii) LDH above or below the median value of the cohort at W0; iii) S100B above or 
below the median value of the cohort at W12; iii) ECOG PS below or above 1. Results indicate that 
the presence of B-RAF mutations or elevated levels of LDH do not affect OS (Fig. 19 A, B), while 
patients with reduced levels of S100B after ipilimumab treatment have a trend toward longer OS 
(Fig. 19 C). As expected, the ECOG performance status is a good predictor of OS (Fig.19 F, P=0.01).  
Besides, we tested whether a significant difference was present between W0 and W12 levels or 
relative variations of VEGF between patients alive or deceases at week 29. The pattern of 
association between VEGF and survival is peculiar; in fact patients with lower baseline levels of 
this protein have a tendency toward a better prognosis (Fig. 19 D), but when we considered the 
relative variation of this parameter, we found that increasing levels of VEGF at W12 were 
associated with longer survival (Fig. 19 E). Hence, the involvement of serum VEGF levels in 
prediction of survival must be further investigated. 
  
Figure 19: Survival estimates according to the clinical characteristics of the patient  
A-B-C-F) Kaplan-Meier estimates for OS according to mutational status of BRAF, LDH at W0, S100B at 
W12 and ECOG PS are shown. D-E) W0, W12 levels and relative variations of VEGF in patients alive or 
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deceased at W29 are shown. Box plots report median, first and third quartiles. Outlier are plotted as 
individual points. Wilcoxon Rank Sum Test was used to compare inter-group variations. Values were 
considered statistically significant for P<0.05. 
T cell subsets 
Ipilimumab releases the inhibitory signals triggered by CTLA-4 on T cells and it is currently believed 
that it activates tumor-specific T cells, whenever they are pre-existing (Snyder NEJM 2014). We 
divided the cohort in two groups according to the survival status at W29. According to this analysis, 
we observed a significant up-regulation of CD3+ T cells frequency in patients alive at W29 (Fig. 20 
A, P=0.023) while survival was not associated with a preferential expansion of CD4+ or CD8+ T cells 
(data not shown), but rather to PD-1 frequencies on the two T cell subsets. Indeed, after 
treatment, PD-1 expression was significantly up-regulated on CD4+ and CD8+ T cells of patients 
alive at W29 (Fig. 20 C P=0.003, Fig 20 E P=0.013) while patients deceased at same time-point had 
stable PD-1 expression on CD4+ cells but statistically increased frequencies of PD-1+ cells within 
CD8+ T lymphocytes (Fig. 20 E, P=0.031). We further confirmed these results using Log-rank 
survival analysis comparing the difference in terms of OS in patients presenting levels of T cell 
subsets below or above the median value of the cohort. Univariate survival analysis confirmed the 
association between increased number of CD3+ T cells and OS and it also demonstrated that an 
increased number of CD3+/CD4+/PD-1+ cells is associated with longer OS (Fig. 20 D P=0.05), while 
a higher absolute variation of PD-1 expression in the CD8+ counterpart predicted a worse 
prognosis (Fig. 20 F P=0.026).  
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Figure 20: Changes in T cell subsets during ipilimumab treatment and association with 
OS 
W0 and W12 frequencies of T cell subsets are reported in panels A, C and E according to the survival 
status of patients at W29. Box plot report median, first and third quartiles. Outlier are plott ed as 
individual points. Significance of intra-group variations between baseline and post-treatment values 
were assed using Wilcoxon Signed Rank Test (* P<0.05). Panels B-C-E) Kaplan-Meier curves estimating 
OS on the base of absolute variation of: CD3+ cell number (B), CD3+/CD4+/PD-1+ cell number (D), and 
frequency of PD-1+ cells within CD8+ T lymphocytes (E). Values were considered statistically significant 
for P<0.05.  
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Myeloid-Derived Suppressor Cells 
We and others demonstrated that MDSC levels correlate with OS in cancer patients78,94,207 
(reviewed in 63); We thus explored the potential association between levels of myeloid subsets 
and OS in ipilimumab-treated patients. To this end we considered W0, W12, absolute and relative 
variation of myeloid subsets and we divided the cohort of patients in two groups according to the 
median value of the parameter under investigation. Difference in OS between the two groups was 
tested using the Log-Rank test and reported using Kaplan-Meier curves (Fig. 21)  
Two out of 3 MDSC subsets expanded at baseline were significantly associated with OS (Fig. 21 A-
B, P=0.024 for MDSC1, P=0.049 for MDSC2). On the contrary, the association between MDSC4 and 
survival stemming from cluster analysis (Fig. 17) was not confirmed by univariate survival analysis 
(P=0.445, data not shown).  
 
 
Figure 21: Kaplan Meier estimates for overall survival according to post-treatment 
frequencies of MDSCs  
Survival curves of patients with levels of MDSC1 (A) and MDSC2 (B) below or above the median of the 
cohort at W12. Values were considered statistically significant for P<0.05.  
In conclusion, our results indicate that OS is associated with some immunological parameters of 
melanoma-treated patients. In fact, multivariate clustering analysis revealed multiple associations 
between survival and hematological parameters, myeloid and T cell subsets. These results were 
confirmed by univariate analysis and we identified two immunological profiles with opposite 
prognosis: lower baseline levels of CRP, IL-6, a better performance status and an expansion of 
CD3+ and CD4+/PD-1+ T cells post-treatment characterize patients with prolonged OS. On the other 
hand, patients with higher frequencies of MDSC1, MDSC2, and CD8+/PD-1+ T cells at W12 had 
significantly reduced OS.  
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Correlation between immune parameters predictors of survival.  
To assess whether early predictors of survival are inter-connected, we correlated baseline and 
post-treatment levels of such TIPs using the Spearman test.  
We found significant correlations within each class of TIPs, and results are shown in Table 4 and 
Figure 22. For example, IL-6 and CRP, two proteins associated with inflammation, were tightly 
connected both at baseline and post-treatment (P<0.001 W0, P=0.007 W12). CRP and IL-6 levels 
significantly correlated also with VEGF levels (P= 0.001 and P=0.002, respectively). We also 
observed a strong correlation between MDSC1 and MDSC2 (P=0.027 W0, P=0.0006 W12), which 
similarly express IL4R.  
Interestingly, significant correlations were present also between different classes of TIPs. For 
example, there was a striking correlation between baseline levels of CRP and the three subsets of 
MDSCs expanded at baseline in melanoma patients, i.e. MDSC1-2-4 (Fig. 22 A-B-C, P<0.001 for 
MDSC1-2-4). This association was not statistically significant for other myeloid subsets, and for 
MDSC3, which were not expanded by these patients at baseline (Table 4). Analogously, baseline 
levels of IL-6 are significantly correlated with MDSCs expansion, in particular with MDSC1 and 
MDSC4 (Fig. 22 D-E, P<0.001 for both MDSC subsets) and the association with MDSC1 was 
maintained also post-treatment (Fig. 22 F P=0.013). Finally, the T cell compartment was not 
significantly linked to serum proteins, but we observed a significant inverse correlation between 
MDSC4 and CD8+ T cells which was present both at baseline and post-treatment (Table 3, P=0.009 
W0 and P=0.026 W12).  
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TIME-POINT 1ST VARIABLE 2ND VARIABLE R P 
BASELINE 
CRP IL-6 0,753 0,0000002 
CRP VEGF 0.525 0.0011 
CRP MDSC1 0.661 0.000114 
CRP MDSC2 0.614 0.000871 
CRP MDSC3 -0.212 0.241 
CRP MDSC4 0.566 0.000785 
CRP Eosinophils -0.269 0.135 
CRP 
Lin-/HLA-DR-
/CD33dim 
-0.267 0.138 
IL-6 VEGF 0.512 0.00211 
IL-6 MDSC1 0.690 0.000067 
IL-6 MDSC2 0.318 0.128 
IL-6 MDSC3 -0.020 0.912 
IL-6 MDSC4 0.589 0.00066 
IL-6 Eosinophils -0.212 0.257 
IL-6 
Lin-/HLA-DR-
/CD33dim 
-0.125 0.506 
MDSC1 MDSC2 0.425 0.027 
MDSC4 CD3+/CD8+ T cells -0.449 0.00904 
POST-TREATMENT 
CRP IL-6 0.488 0.00745 
IL-6 MDSC1 0.498 0.013 
MDSC1 MDSC2 0.648 0.000608 
MDSC4 CD3+/CD8+ T cells -0.436 0.0261 
 
 
Table 4: Correlation between levels of tumor-associated and immunological parameters 
Baseline and post-treatment levels of TIPs were correlated using Spearman Correlation. The two 
variable undergoing the correlation test are indicated as “1 st variable” and 2nd variable”. Values were 
considered statistically significant for P<0.05.  
86 
 
 
Figure 22: Correlation between serum proteins and MDSCs 
Spearman Correlation was used to assess correlation between CRP levels and frequencies of MDSC1 
(A), MDSC2 (B) and MDSC4 (C) at W0; IL-6 levels and frequencies of MDSC1 (D) or MDSC4 (E) at W0; 
IL-6 levels and MDSC1 frequencies at W12. R, coefficient of correlation. Values were considered 
statistically significant for P<0.05.  
The results from this correlation analysis revealed a net of connections that could open new 
working hypothesis. For example, the correlations between IL-6, CRP, MDSC1 and MDSC2 suggest 
a possible connection between cancer-associated inflammation and expansion of MDSCs and it is 
of particular interest if we consider that these four parameters are among the strongest predictors 
of OS identified by this study.  
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DISCUSSION 
Ipilimumab was the first ICI showing an OS benefit in metastatic melanoma and a number of 
studies demonstrated the predictive role of immunological parameters as surrogate biomarkers 
of clinical response to this treatment (reviewed in 175). Besides, the identification of predictive and 
pharmacodynamic biomarkers is fundamental to select patients with higher probability of 
response to this expensive treatment, also in the view of the promising effect of combined 
approaches using PD-1 and CTLA-4 blockade. Circulating levels of MDSCs have been correlated to 
tumor burden and OS in different types of cancer, and some studies demonstrated their 
prognostic role for the outcomes of different chemotherapeutic regimens (reviewed in 63), thus 
becoming a promising biomarker also for response to immunotherapy. However, the validation of 
the predictive significance of MDSCs in multicenter studies is complicated by the phenotypic 
complexity of human MDSCs, thus creating a challenge in finding a consensus on the minimal 
requirements for MDSC monitoring. To meet this request, we organised the first proficiency panel 
to harmonize human MDSC phenotyping. Compared to other proficiency panels, the MDSC panel 
was challenging in terms of number of participants, complexity of the staining panel and number 
of subsets to be identified. Given these premises, it is not surprising that the quantification of the 
10 requested MDSC subsets was characterised by a high inter-laboratory variance, increasing from 
monocytic to immature and granulocytic subsets. The number and the international origin of the 
participating laboratories indicate that the high inter-laboratory variance observed in the panel 
could be similarly implied also in studies on human MDSC published. On the contrary, the intra-
laboratory variance was acceptable indicating that the participating laboratories were 
experienced in the field of multicolour flow cytometry.  
We identified three critical parameters that impacted on the quantification of MDSC phenotyping: 
the choice of reagents, the use of a DCM and the gating strategy. As staining reagents were 
relatively free of choice, a considerable number of different antibodies were used to identify 
MDSC subsets using an 8-color staining panel. As a result, we observed that the clone of anti-
CD124 antibody and the composition of the Lineage cocktail significantly influenced the 
quantification of CD124+ MDSCs and immature MDSCs, respectively. Indeed, this problem was 
also identified by previous proficiency panels in which a partial standardization of reagents was 
suggested194, especially for culturing of PBMCs intended to functional T cell assays193,208,209. 
The MDSC proficiency panel introduced the use of a DCM, and we observed that the quantification 
of several MDSC subsets, and in particular of granulocytic ones, was significantly reduced by dead 
cell exclusion. Hence, these results open the discussion whether it is worth to quantify also dead 
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MDSCs because they were most likely present and alive in the fresh sample, or whether inclusion 
of dead cells could alter MDSC quantification due to unspecific binding of antibodies to other cell 
types. 
Besides the choice of the reagents, we found that the gating strategies used for identification of 
MDSC subsets had a significant influence on the variance of results. Indeed, when we included in 
the analysis only those laboratories which applied a homogenous gating strategy, similar to that 
proposed in the panel’s guidelines, we observed a significantly improved inter-laboratory 
performance. This was not unexpected since most of the proficiency panels based on flow 
cytometry similarly recommended to harmonize the gating strategies across laboratories. In a 
multimer-based proficiency panel, results were audited in order to exclude wet-laboratories 
which regularly used a wrong gating procedure194. However, since identification of MDSC subsets 
derive from a complex combination of signals, we believe that a more adequate approach is to 
train the participating laboratories to perform a properly gating pipeline through an in-silico panel, 
as done in ICS proficiency panels193,210. In addition, this in-silico approach may be further used by 
participants as learning module for training operators in order to reduce intra-laboratory variance. 
Overall, we demonstrated that it is feasible to conduce a proficiency panel including such a large 
number of participants and identifying a high number of myeloid subsets using 8-color flow 
cytometry. In this first step, we provided individual feedback of performance for each laboratory 
and we identified a number of parameters that must be harmonized in the second step, hence 
establishing the foundation for the development of a robust assay for MDSC phenotyping.  
From this experience, we developed a method to reduce inter-assay variance of MDSC 
phenotyping and we used this standardized approach to monitor the circulating levels of four 
MDSC subsets in melanoma patients receiving ipilimumab. Several non-overlapping MDSC 
phenotypes have been described198, classified as immature, monocytic and granulocytic subsets, 
but most of the studies reduced MDSC monitoring to only one phenotype. We believe that all the 
subsets should be investigated in clinical studies for a complete overview of MDSC expansion, and 
the results from the first phase of the proficiency panel demonstrated that this is a feasible 
objective. To date, only the study by Walter and colleagues monitored six MDSC subsets 
simultaneously in renal cell carcinoma patients, and found that five out of six subsets were 
significantly expanded in the blood and, moreover, that the levels of two out of the six subsets 
were negatively associated with OS in response to a multipeptide-based vaccination protocol94. In 
line with these results, we observed that also melanoma patients significantly expanded more 
than one MDSC subset, thus suggesting the presence of immune suppression in these patients. In 
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particular, the cohort under investigation expanded three MDSC subsets (MDSC1-2-4) which were 
originally discovered in melanoma patients and further described also in other types of cancer 
(reviewed in 63). In addition, in a previous study we demonstrated that the expression of IL4R on 
monocytes (MDSC1) of cancer patients was directly correlated with inhibition of T cell 
proliferation70. Evidence form mouse models indicated that IL4R is involved in MDSC function69,71 
and survival69, but the functional role of this marker in human MDSCs in still under investigation. 
Recently Kitano and colleagues addressed the problem of standardization of MDSCs, and 
developed a computational algorithm-based method to perform a uniform analysis of the levels 
of MDSC4 in melanoma patients treated with two different doses of ipilimumab (3mg/kg or 
10mg/kg)176. This was the first study reporting a significant association between baseline levels of 
MDSC4 and OS, independently of LDH levels and absolute lymphocytes count, but the prognostic 
significance of MDSCs was restricted only to patients receiving the higher dose of ipilimumab. In 
our study, in which ipilimumab was administered at 3 mg/kg, we did not observed any association 
between baseline levels of MDSCs and OS. Nevertheless, we identified, by cluster analysis, that 
post-treatment levels of MDSC4 were significantly reduced in the group of patients with longer 
survival and that a significant inverse correlation between these cells and CD8+ T cells was present 
at W0 as well as at W12. A similar inverse correlation was observed, in two independent studies, 
both in non-treated lung cancer patients211 and in melanoma patients receiving 
ipilimumab176.These findings probably reflect the balance between suppressive and effector 
leukocytes characterising the immunological profile of cancer patients, and ipilimumab could alter 
this equilibrium by boosting T cell responses which, in turns, contrast the action of immune 
suppression exerted by MDSCs.  
This is not the first evidence of a prognostic role for MDSCs, in fact the levels of MDSCs have been 
associated to OS and response to different chemotherapeutic regimens both at baseline and post-
treatment77,78,88,93,207,211,212. However, in view of the immune-mediated effect of ipilimumab, lower 
levels of suppressive cells could represent not only an estimator of clinical benefit but also a 
pharmacodynamic biomarker, reflecting the shift from immune escape to immune-response. In 
fact, using a multivariate non-parametric statistical approach, we demonstrated that a survival 
benefit can be estimated on the base of decreasing levels of monocytic and granulocytic MDSCs, 
expressing IL4R (MDSC1 and MDSC2) and a parallel increase in the number of T cells, which 
indeed may reflect the conversion from escape to rejection phase. The role of MDSCs as a 
biomarker for ipilimumab treatment was demonstrated in a number of studies, mostly reporting 
correlations between MDSC4 and clinical response181,191,213. Only one study monitored 
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granulocytic MDSC in ipilimumab-treated patients describing a significant reduction of the 
granulocytic subset coupled with down-regulation of Arginase-1 expression on the whole myeloid 
compartment190. 
Given the reliability of MDSCs as biomarker of clinical outcomes to ipilimumab treatment, it 
remains to be clarified whether ipilimumab targets MDSCs or, conversely, if the decreasing levels 
of MDSCs observed following ipilimumab treatment simply reflect the shrinkage of the tumor in 
response to immune rejection. Even if a direct evidence of CTLA-4 expression by MDSCs is still 
missing, we believe that it would be important to understand the possible direct targeting of 
MDSCs by anti-CTLA-4, and different intriguing hypothesis could be derived by the experience 
matured on DCs. Indeed, from one side, CTLA-4 expressing DCs showed an impaired maturation 
profile, reduced stimulatory function214 and produced IL-10 215, as MDSCs. On the other side, CTLA-
4 could act on DCs also by reverse signalling through CD80/CD86. Grohmann and colleagues 
demonstrated that CD80/CD86 ligation by CTLA-4-Ig induced IDO expression in DCs and a 
consequent functional impairment of T cells216; Since IDO has a role in the mechanism of MDSC 
suppression85, the reverse signalling described for DCs could be active also in these cells and, 
according to this hypothesis, ipilimumab would relieve T cell activation both following a T-cell 
intrinsic pathway and through reduction of the suppressive function of MDSCs. 
Another strategy to track the onset of immune rejection triggered by ipilimumab is to monitor the 
activation and functional status of T cells. In fact, absolute lymphocyte count is one of the first 
parameter identified as strongly associated to clinical effect of ipilimumab176-179,183,188, and many 
studies characterized the immune correlates of this drug. As expected, T cells of responding 
patients displayed an activated phenotype, expressing ICOS or HLA-DR186,187,217, increased antigen 
specific responses180,187 and boosted IFN- production which was correlated to a Th1-associated 
signature at the tumor site182. However, less is known about the expression of other immune 
checkpoint molecules in response to the blockade of CTLA-4. We also monitored the levels of PD-
1 expression on T cells in response to ipilimumab and we found that melanoma patients expressed 
significantly higher levels of PD-1 in the CD4+ compartment at baseline. Moreover, T cells further 
up-regulated PD1 on both CD4+ and CD8+ T cell subsets upon treatment. Of note, post-treatment 
variation of PD-1 expression on the two subsets was differently associated with OS: in fact, 
patients with longer OS increased the absolute count of CD4+/PD-1+ T cells during the treatment, 
while those with higher expression of PD-1 on the CD8+ counterpart had a reduced OS.  
Only one study investigated the expression of PD-1 on T cells during ipilimumab, and it showed an 
up-regulation of this marker on T cells after the first dose, followed by a sudden down-regulation 
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of PD-1 expression at the end of the treatment. Interestingly, also the relative frequencies of Tregs 
were evaluated in this study, and the variation of these cells had the same trend of expression of 
PD-1 on T lymphocytes190.  
Since in our cohort of patients the expansion of CD4+/PD-1+ T cells was associated with reduced 
toxicity, we speculated that increasing frequencies of these cells was due to an expansion of Tregs. 
This hypothesis is based on the fact that PD-1 and CTLA-4 play an important role in Treg induction 
and functional activity163,218. In addition, the constitutive expression of CTLA-4 on Tregs suggests 
a potential effect of ipilimumab on this cell subset145. However, this hypothesis is only partially 
supported by evidence from the literature because the presence of Tregs was monitored in 
ipilimumab-treated patients with conflicting results which make the predictive power of Treg not 
extensively reliable177,181,183,190.  
On the contrary, the association between higher PD-1 expression on CD8+ T cells and reduced OS 
suggests the induction of an exhausted phenotype on cytotoxic T cells. However, in a recent report 
PD-1 and Lag-3 expression were significantly down-regulated following blockade of PD-1 and/or 
CTLA-4 on the surface of CD8+ T cells specific for antigenic mutant epitopes driving the immune-
rejection of the tumor99. Hence, further characterisation of CD8+/PD-1+ cells is needed because 
PD-1 expression alone does not permit to define unambiguously an exhausted cell, which is indeed 
characterised by the expression of multiple inhibitory checkpoint molecules like Tim-3, Lag-3, 
BTLA-421. 
In addition to circulating MDSC and T cell subsets, we observed that the pro-inflammatory 
cytokine IL-6 was a strong estimator of OS in response to ipilimumab, while a trend toward 
association was present between survival and other markers of inflammation like VEGF and CRP. 
Given the predictive and prognostic power of inflammatory proteins and MDSCs described so far, 
it is important to consider that baseline levels of these parameters were highly interconnected, 
thus supporting the existence of an immunological loop associated with OS in response to 
ipilimumab. In fact, CRP and IL-6 significantly correlated with the circulating levels of the MDSC 
subsets expanded at baseline (MDSC1/MDSC2/MDSC4). These correlations suggest the presence 
of a suppressive net at the tumor site, spreading to the circulation, in which inflammatory proteins 
induce MDSCs and regulate their suppressive functions as previously demonstrated in murine 
models219 (reviewed in 25) and in human cells in-vitro 32,220. In addition, the down-stream mediator 
of IL-6 signalling, signal transducer and activator of transcription 3 (STAT-3), regulated the 
suppressive activity of tumor-infiltrating MDSC from head and neck squamous cell carcinoma 
patients through modulation of arginase 1 activity221. The connection observed in our study 
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between IL-6, MDSC levels and OS suggests the hypothesis of a combination therapy of anti-IL-6 
mAb and immune-checkpoint inhibitors. From one side, IL-6 blockade could enhance the efficacy 
of immune checkpoint inhibitors by disrupting the mechanisms of immune escape at the tumor 
site, and from the other side, it could also reduce the toxicity of this treatment, which is 
characterised by autoimmune responses. Indeed, blockade of IL-6 pathway is currently approved 
for the treatment of autoimmune diseases, like rheumatoid arthritis, and combinations of anti-IL-
6 and chemotherapy are already under development in phase I studies for cancer treatment 
(reviewed in 222).  
 In addition to prediction of survival, the present study was also designed to identify an immune 
profile associated with the development of irADR due to ipilimumab treatment. Albeit early 
reports indicated that the onset of irADR was prognostic of response to ipilimumab205,206, the 
potential link between irADR and clinical benefit awaits further confirmation from large 
perspective studies. Our results indicate that the development of toxicity was not predictive for 
longer OS in response to ipilimumab. However in our study, toxicity was associated with a defined 
immune profile characterised by reduced CD3+ T cells, increased variance in MDSC4 and lower 
frequencies of eosinophils. In addition, patients with lower toxicity significantly expanded PD-1+ T 
lymphocytes compared to those experiencing grade 3 irADR. As the prediction of toxicity was less 
investigated in clinical studies, our results constitute a first attempt to characterise the immune 
profile of patients prone to toxicity and are supported only by the study of Wang and colleagues. 
In this study, Authors observed that the onset of irADR was associated with lower frequencies of 
proliferating, Ki67+, CD4 and CD8 T lymphocytes185. In particular, patients free from toxicity 
expanded a subset of CD4+ T cells expressing eomesodermin, a transcription factor that regulates 
the generation of memory T cells223 and, similarly to our results, was associated to increased PD-
1 expression224. 
In conclusion, this study explored different aspects of immunomonitoring of ipilimumab-treated 
melanoma patients and it constitutes from one side a preparatory step for the development of a 
robust assay for MDSC identification, and from the other side it defines the immune profile of 
patients that most likely benefit from ipilimumab treatment. Our results should be further 
validated in an independent cohort of ipilimumab-treated patients, nevertheless they constitute 
an important first step towards identification of biomarkers that improve the clinical use of 
immune checkpoint inhibitors.  
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